Use these links to rapidly review the document
TABLE OF CONTENTS
TABLE OF CONTENTS


CALCULATION OF REGISTRATION FEE

               
 
Title of Each Class of Securities
to be Registered

  Amount to be
Registered

  Maximum Offering
Price Per Unit

  Maximum Aggregate
Offering Price

  Amount of
Registration Fee

 

Alexandria Real Estate Equities, Inc. 3.90% Senior Notes due 2023

  $500,000,000   99.712%   $498,560,000   $68,003.59(1)
 

Alexandria Real Estate Equities, L.P. Guarantee of 3.90% Notes due 2023

  (2)   (2)   (2)   (2)

 

(1)
The filing fee of $68,003.59 is calculated in accordance with Rules 457(o) and 457(r) of the Securities Act of 1933, as amended, or the Act. In accordance with Rules 456(b) and 457(r) of the Act, the registrants initially deferred payment of all of the registration fees for the Registration Statement filed by the registrants on June 5, 2012.

(2)
No separate consideration will be received for the guarantee. Pursuant to Rule 457(n) under the Act, no separate fee is payable with respect to the guarantee being registered hereby.

Table of Contents

Filed Pursuant to Rule 424(b)5
Registration File No: 333-181881

PROSPECTUS SUPPLEMENT
(To prospectus dated June 4, 2012)

$500,000,000

LOGO

Alexandria Real Estate Equities, Inc.

3.90% Senior Notes due 2023
Fully and Unconditionally Guaranteed by Alexandria Real Estate Equities, L.P.



        We are offering $500,000,000 of 3.90% senior notes due 2023.

        The notes will bear interest at the rate of 3.90% per year. Interest on the notes is payable on December 15 and June 15 of each year, beginning on December 15, 2013. The notes will mature on June 15, 2023. The notes will be fully and unconditionally guaranteed by our subsidiary, Alexandria Real Estate Equities, L.P., a Delaware limited partnership. We may redeem some or all of the notes at any time prior to maturity and as described under the caption "Description of Notes and Guarantee—Our Redemption Rights." If the notes are redeemed on or after 90 days prior to the maturity date, the redemption price will not include a make-whole provision. We will issue the notes only in registered form in denominations of $2,000 and integral multiples of $1,000 in excess thereof.

        The notes will be our unsecured senior obligations and will rank equally in right of payment with all of our other unsecured senior indebtedness from time to time outstanding and will be effectively subordinated in right of payment to all of our existing and future secured indebtedness and to all existing and future liabilities and preferred equity, whether secured or unsecured, of our subsidiaries other than Alexandria Real Estate Equities, L.P.

        No market currently exists for the notes. We do not intend to list the notes on any national securities exchange.

        Investing in our notes involves risks. See "Risk Factors" on page S-11.

             
   
 
  Per Note
  Total(1)
 
   

Public offering price

    99.712%   $ 498,560,000  
   

Underwriting discounts and commissions

    0.650%   $ 3,250,000  
   

Proceeds, before expenses, to us

    99.062%   $ 495,310,000  

 

 
(1)
Plus accrued interest, if any, from the original date of issue.

        Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

        The underwriters expect to deliver the notes in book-entry form only through the facilities of The Depository Trust Company against payment on or about June 7, 2013.



J.P. Morgan   RBC Capital Markets   RBS

Barclays

 

Goldman, Sachs & Co.

 

Mitsubishi UFJ
Securities

 

PNC Capital
Markets LLC

 

Scotiabank

BBVA Securities

 

BNY Mellon Capital Markets, LLC

 

Credit Agricole CIB

 

Credit Suisse

Fifth Third Securities, Inc.

 

HSBC

 

Huntington Investment Company

 

JMP Securities

 

TD Securities

The date of this prospectus supplement is May 29, 2013.


Table of Contents


TABLE OF CONTENTS

 
  Page  

Prospectus Supplement

 

Forward-Looking Statements

    ii  

Summary

    S-1  

Risk Factors

    S-11  

Alexandria Real Estate Equities, Inc. 

    S-14  

Properties

    S-25  

Use of Proceeds

    S-36  

Capitalization

    S-37  

Description of Notes and Guarantee

    S-38  

Federal Income Tax Considerations

    S-51  

Underwriting (Conflicts of Interest)

    S-55  

Legal Matters

    S-60  

Experts

    S-60  

Prospectus

 

About this Prospectus

    ii  

Risk Factors

    1  

Where You Can Find More Information

    1  

The Company

    3  

Securities That May Be Offered

    3  

Use of Proceeds

    4  

Consolidated Ratios of Earnings to Fixed Charges and Combined Fixed Charges and Preferred Stock Dividends

    5  

Description of Stock

    6  

Description of Rights

    12  

Description of Warrants

    13  

Description of Debt Securities and Related Guarantees

    14  

Description of Global Securities

    20  

Provisions of Maryland Law and of Our Charter and Bylaws

    23  

Federal Income Tax Considerations

    27  

Plan of Distribution

    40  

Legal Matters

    41  

Experts

    41  

Forward-Looking Statements

    41  



        You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and the underwriters have not, authorized any other person to provide you with any different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference is accurate only as of their respective dates. Our business, financial condition, results of operations, and prospects may have changed since those dates.

i


Table of Contents


FORWARD-LOOKING STATEMENTS

        This prospectus supplement and the accompanying prospectus contain or incorporate by reference forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify the forward-looking statements by their use of forward-looking words, such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates," or "anticipates," or the negative of those words or similar words. Forward-looking statements involve inherent risks and uncertainties regarding events, conditions, and financial trends that may affect our future plans of operation, business strategy, results of operations, and financial position. A number of important factors could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including, but not limited to the following:

ii


Table of Contents

        This list of risks and uncertainties is not exhaustive. For a discussion of these and other factors that could cause actual results to differ from those contemplated in the forward-looking statements, please see the discussion under "Risk Factors" contained in this prospectus supplement and the other information contained in our publicly available filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013. We do not undertake any responsibility to update any of these factors or to announce publicly any revisions to forward-looking statements, whether as a result of new information, future events, or otherwise.

iii


Table of Contents


SUMMARY

        The following summary may not contain all of the information that is important to you. You should read this entire prospectus supplement, the accompanying prospectus, and the documents incorporated by reference into the accompanying prospectus carefully before deciding whether to invest in the notes. In this prospectus supplement and the accompanying prospectus, unless otherwise indicated, the "Company," "we," "us," and "our" refer to Alexandria Real Estate Equities, Inc. and its subsidiaries, and "GAAP" refers to accounting principles generally accepted in the United States. Unless otherwise indicated, the information in this prospectus supplement is as of March 31, 2013.


Alexandria Real Estate Equities, Inc.

Overview

        We are a self-administered and self-managed investment grade REIT. We are the largest and leading REIT focused principally on owning, operating, developing, redeveloping, and acquiring high-quality, sustainable real estate for the broad and diverse life science industry. Founded in 1994, we are the first REIT to identify and pursue the laboratory niche and have since had the first-mover advantage in the core life science cluster locations, including Greater Boston, San Francisco Bay Area, San Diego, New York City, Seattle, Suburban Washington, D.C., and Research Triangle Park. Our high-credit client tenants span the life science industry, including renowned academic and medical institutions, multinational pharmaceutical companies, public and private biotechnology entities, U.S. government research agencies, medical device companies, industrial biotech companies, venture capital firms, and life science product and service companies.

        Our primary business objective is to maximize stockholder value by providing our stockholders with the greatest possible total return and long-term asset value based on a multifaceted platform of internal and external growth. The key elements to our strategy include our consistent focus on high-quality assets and operations in the top life science cluster locations with our properties located in close proximity to life science entities, driving growth and technological advances within each cluster. These locations are characterized by high barriers to entry for new landlords, high barriers to exit for client tenants, and limited supply of available space. They represent highly desirable locations for tenancy by life science entities because of the close proximity to concentrations of specialized skills, knowledge, institutions, and related businesses. Our strategy also includes drawing upon our deep and broad life science and real estate relationships in order to attract new and leading life science client tenants and value-added real estate.

        Recent Developments:

 

S-1


Table of Contents

        As of March 31, 2013:

Growth and Core Operating Strategies

        We continue to demonstrate the strength and durability of our core operations, providing life science laboratory space to the broad and diverse life science industry. Our internal growth has been consistent, as demonstrated by our same property net operating income ("NOI") performance, high and relatively stable occupancy, and continuing improvement of cash flows from the leasing activity of our core operating assets. In addition, we continue to focus on our external growth through the conversion of non-income-producing assets into income-producing assets, which results in cash flow contribution from ground-up development and from redevelopment of non-laboratory space into laboratory space. We intend to selectively acquire properties that we believe provide long-term value to our stockholders. Our strategy for acquisitions will focus on the quality of the submarket locations, improvements, tenancy, and overall return. We believe the life science industry will remain keenly

 

S-2


Table of Contents

focused on locations in close proximity to key innovation drivers in each major life science submarket. Owning and operating the best assets in the best locations provides the best upside potential and provides the most downside risk mitigation. This being the case, we will also focus on locations that we believe will deliver high cash flows, stability, and returns as we work to deliver the highest value to our stockholders.

        We also intend to continue to focus on the completion and delivery of our existing active development and redevelopment projects in North America, aggregating approximately 1,854,859 RSF, and 331,380 RSF, respectively. Additionally, we intend to continue with preconstruction activities for certain land parcels for future ground-up development in order to preserve and create value for these projects. These important preconstruction activities add significant value to our land for future ground-up development and are required for the ultimate vertical construction of the buildings. We also continue to be very prudent with any future decisions to add new projects to our active ground-up developments. Future ground-up development projects will likely require significant pre-leasing from high-quality and/or creditworthy entities.

        We intend to continue to transition our balance sheet debt from short-term and medium-term unsecured variable rate bank debt to long-term unsecured fixed rate debt. We are focused on the recycling of sale proceeds from non-core suburban assets for investment into higher-value urban or central business district ("CBD") assets and teaming with high-quality capital partners, as appropriate. We expect sources of funds for construction activities and repayment of outstanding debt to be provided by opportunistic sales of real estate, joint ventures, cash flows from operations, new secured or unsecured debt, and the issuance of additional equity securities, as appropriate. We intend to combine these sources of capital in order to achieve and maintain our overall balance sheet leverage target.

        We seek to maximize balance sheet liquidity and flexibility, cash flows, and cash available for distribution to our stockholders through the ownership, operation, management, and selective acquisition, development, and redevelopment of life science properties, as well as management of our balance sheet. In particular, we seek to maximize balance sheet liquidity and flexibility, cash flows, and cash available for distribution by:

 

S-3


Table of Contents

We continue to target achieving a leverage ratio of net debt to adjusted EBITDA of approximately 6.5x and a fixed charge coverage ratio of approximately 3.0x as of December 31, 2013.

First Quarter 2013 Highlights

Core Operating Metrics

 

S-4


Table of Contents

        FFO per share—diluted, AFFO per share—diluted, NOI, and same property NOI are non-GAAP measures. For information on the Company's FFO, AFFO, NOI, and same property NOI, including definitions and reconciliations to the most directly comparable GAAP measures, see page S-28.

Value-Added Opportunities and External Growth

        As of March 31, 2013, we had six ground-up development projects in process in North America, including an unconsolidated joint venture development project, aggregating approximately 1,854,859 RSF. We also had seven active projects undergoing conversion into laboratory space through redevelopment, aggregating approximately 331,380 RSF. These projects, along with recently delivered projects, certain future projects, and contribution from same properties, are expected to contribute significant increases in rental income, NOI, and cash flows.

        During the three months ended March 31, 2013, we executed leases aggregating 355,000 and 102,000 RSF, respectively, related to our development and redevelopment projects.

        Our initial stabilized yield on a cash basis reflects cash rents at date of stabilization and does not reflect contractual rent escalations beyond the stabilization date. Our cash rents related to our value-added projects are expected to increase over time and our average stabilized cash yields are expected, in general, to be greater than our initial stabilized yields. Initial stabilized yield is calculated as the ratio of the estimated amounts of NOI and our investment in the property at stabilization ("Initial Stabilized Yield").

        The following table summarizes the commencement of key development projects during the three months ended March 31, 2013 (dollars in thousands, except per RSF amounts):

 
   
   
   
   
   
  Initial
Stabilized
Yield
   
 
  Commencement
Date
   
  Pre-Leased
%
  Investment at
Completion
  Cost
Per RSF
  Key
Client Tenant
Address/Market
  RSF   Cash   GAAP

Development

                                           

75/125 Binney Street/Greater Boston

  January 2013     386,275     63 % $ 351,439   $ 910     8.0 %   8.2 % ARIAD Pharmaceuticals, Inc.

269 East Grand Avenue/San Francisco Bay Area

  March 2013     107,250     100 % $ 51,300   $ 478     8.1 %   9.3 % Onyx Pharmaceuticals, Inc.

Balance Sheet Strategy and Significant Milestones

        Our balance sheet strategy will continue to focus on achieving a target leverage ratio of net debt to adjusted EBITDA of approximately 6.5x and a fixed charge coverage ratio of approximately 3.0x as of December 31, 2013, by funding our significant Class A development and redevelopment projects in top life science cluster locations with leverage-neutral sources of capital and with the continuing execution of our asset recycling program. Our leverage will reflect periodic increases and decreases quarter to quarter as we execute and deliver our construction projects and execute our capital plan, including our

 

S-5


Table of Contents

asset recycling program. Our balance sheet objective and our strategy to achieve and maintain our target leverage ratio includes the following:

 

S-6


Table of Contents


The Offering

        The summary below describes the principal terms of the notes. Certain of the terms and conditions described below are subject to important limitations and exceptions. The section entitled "Description of Notes and Guarantee" of this prospectus supplement contains a more detailed description of the terms and conditions of the notes and the indenture governing the notes. As used in this section, unless stated otherwise, the terms "we," "us," "our," and the "Company" refer to Alexandria Real Estate Equities, Inc. and not to any of its subsidiaries, and references to the "Operating Partnership" or "guarantor" refer solely to Alexandria Real Estate Equities, L.P. and not to any of its subsidiaries.

Issuer   Alexandria Real Estate Equities, Inc.

Guarantor

 

Alexandria Real Estate Equities, L.P.

Issuer/Guarantor Structure

GRAPHIC


(1)
As of March 31, 2013. For purposes of this chart, the operating properties have been classified at the lowest level at which a majority ownership is held for the entities shown.
(2)
Composed of our 4.60% unsecured senior notes payable due 2022 ("4.60% unsecured senior notes payable").
(3)
Composed of our unsecured senior bank term loan with a principal of $750 million (as of March 31, 2013) and a maturity date of June 30, 2016 ("2016 unsecured senior bank term loan") and our unsecured senior bank term loan with a principal of $600 million (as of March 31, 2013) and a maturity date of January 31, 2017 ("2017 unsecured senior bank term loan"). Our maturity dates for these two term loans assume that we exercise available one year extension options on each loan.

 

S-7


Table of Contents

Securities Offered   $500,000,000 principal amount of 3.90% notes due 2023.

Ranking

 

As of March 31, 2013, we had outstanding $730.7 million of secured indebtedness and $2.45 billion of senior unsecured indebtedness (exclusive of trade payables, distributions payable, accrued expenses and committed letters of credit) on a consolidated basis. All of our outstanding secured indebtedness as of March 31, 2013 was attributable to indebtedness of our subsidiaries other than Alexandria Real Estate Equities,  L.P.

 

 

The notes will be our senior unsecured obligations and will rank equally with each other and with all of our existing and future other senior unsecured indebtedness. However, the notes will be effectively subordinated to our existing and future mortgages and other secured indebtedness (to the extent of the value of the collateral securing such indebtedness) and to all existing and future preferred equity and liabilities, whether secured or unsecured, of our subsidiaries other than Alexandria Real Estate Equities, L.P.

Guarantee

 

The notes will be fully and unconditionally guaranteed by Alexandria Real Estate Equities, L.P. The guarantee will be a senior unsecured obligation of Alexandria Real Estate Equities, L.P. and will rank equally in right of payment with other senior unsecured obligations of Alexandria Real Estate Equities, L.P.

Interest

 

The notes will bear interest at a rate of 3.90% per year. Interest will be payable semi-annually in arrears on December 15 and June 15 of each year, beginning on December 15, 2013.

Maturity

 

The notes will mature on June 15, 2023 unless previously redeemed by us at our option prior to such date.

Our Redemption Rights

 

At any time before 90 days prior to the maturity date, we may redeem the notes at our option and in our sole discretion, in whole or from time to time in part, at the redemption price specified herein. If the notes are redeemed on or after 90 days prior to the maturity date, the redemption price will be equal to the sum of 100% of the principal amount of the notes being redeemed, plus accrued and unpaid interest thereon. See "Description of Notes and Guarantee—Our Redemption Rights" in this prospectus supplement.

Certain Covenants

 

The indenture governing the notes contains certain covenants that, among other things, limit our, our guarantor's and our subsidiaries' ability to:

 

consummate a merger, consolidation or sale of all or substantially all of our assets, and

 

incur secured or unsecured indebtedness.

 

S-8


Table of Contents

    These covenants are subject to a number of important exceptions and qualifications. See "Description of Notes and Guarantee" in this prospectus supplement.

Use of Proceeds

 

We expect that the net proceeds of this offering will be approximately $494.3 million, after deducting the underwriters' discounts and commissions and our estimated offering expenses. We intend to use the net proceeds from this offering to prepay $150 million of the outstanding principal balance of our 2016 unsecured senior bank term loan, to reduce the outstanding balance on our unsecured senior line of credit to zero, and to hold the remaining proceeds in cash and cash equivalents to fund near term opportunities related to development/redevelopment projects, to fund near term property acquisitions, and for general corporate purposes. After reducing the outstanding balance of our unsecured senior line of credit to zero, the Company may also borrow from time to time under such line of credit for any of the foregoing purposes.

Trading

 

The notes are a new issue of securities with no established trading market. We do not intend to apply for listing of the notes on any securities exchange or for quotation of the notes on any automated dealer quotation system. The underwriters have advised us that they intend to make a market in the notes. However, the underwriters will have no obligation to do so, and we cannot assure you that a market for the notes will develop or be maintained.

Book-Entry Form

 

The notes will be issued in the form of one or more fully-registered global notes in book-entry form, which will be deposited with, or on behalf of, The Depository Trust Company, commonly known as DTC. Beneficial interests in the global certificate representing the notes will be shown on, and transfers will be effected only through, records maintained by DTC and its direct and indirect participants and such interests may not be exchanged for certificated notes, except in limited circumstances.

Additional Notes

 

We may, without the consent of holders of the notes, increase the principal amount of the notes by issuing additional notes in the future on the same terms and conditions, except for any difference in the issue price and interest accrued prior to the issue date of the additional notes, and with the same CUSIP number as the notes offered hereby so long as such additional notes are fungible for U.S. federal income tax purposes with the notes offered hereby.

 

S-9


Table of Contents

Conflicts of Interest   Affiliates of certain of the underwriters are lenders under our unsecured senior line of credit and our 2016 unsecured senior bank term loan and will receive a portion of the net proceeds from this offering. See "Underwriting—Conflicts of Interest" and "Underwriting—Other Relationships" in this prospectus supplement.

Risk Factors

 

In analyzing an investment in the notes we are offering pursuant to this prospectus supplement, you should carefully consider, along with other matters included or incorporated by reference in this prospectus supplement, the information set forth under "Risk Factors" beginning on page S-6.

 

S-10


Table of Contents


RISK FACTORS

        An investment in our notes involves risks. New risks may emerge at any time and we cannot predict such risks or estimate the extent to which they may affect our financial performance. You should carefully consider the risks referred to in the section of the accompanying prospectus entitled "Forward-Looking Statements," as well as the risks identified in this prospectus supplement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, which are incorporated herein by reference.


Risks Relating to this Offering

Our business operations may not generate the cash needed to service our indebtedness.

        We cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will enable us to pay our indebtedness, including the notes we are offering in this prospectus supplement. If our cash flows and future borrowings are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets or operations, seek additional capital or restructure or refinance our indebtedness, including the notes. We cannot assure you that we would be able to take any of these actions, that these actions would be successful and permit us to meet our scheduled debt service obligations or that these actions would be permitted under the terms of our existing or future debt agreements. In the absence of such operating results and resources, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt service and other obligations.

The effective subordination of the notes and guarantee may limit our ability to satisfy our obligations under the notes.

        The notes are unsecured and therefore effectively will be subordinated to any of our and our subsidiaries' existing and future secured obligations. As a result, in the event of a bankruptcy, liquidation, dissolution, reorganization or similar proceeding of our Company and/or the guarantor of the notes, our assets and the assets of the guarantor will be available to satisfy obligations of our secured debt before any payment may be made on the notes. To the extent that our assets and the assets of the guarantor cannot satisfy in full our secured debt, the holders of such debt would have a claim for any shortfall that would rank equally in right of payment with the notes. In such an event, we may not have sufficient assets remaining to pay amounts on any or all of the notes.

        The notes will be issued by us and guaranteed only by the guarantor. Any claims of holders of the notes to the assets of our subsidiaries other than the guarantor derive from our direct and indirect equity interests in those subsidiaries. Claims of our subsidiaries' creditors (including general creditors and taxing authorities) will generally have priority as to the assets of our subsidiaries over our own equity interest claims and will therefore have priority over the holders of the notes. Consequently, the notes will be effectively subordinated to all liabilities, whether or not secured, of such subsidiaries, and possibly of any subsidiaries that we may in the future acquire or establish, as well as any indebtedness that may be incurred or guaranteed by certain of our existing and future subsidiaries other than the guarantor.

        All of our outstanding secured indebtedness as of March 31, 2013, was attributable to indebtedness of our subsidiaries other than the guarantor. As of March 31, 2013, all of our outstanding senior unsecured indebtedness was attributable only to the Company and the guarantor, and will rank pari passu with the notes.

S-11


Table of Contents

We will continue to have the ability to incur debt after this offering; if we incur substantial additional debt, these higher levels of debt may affect our ability to pay principal and interest on the notes.

        Although the agreements governing our unsecured credit facility and certain other indebtedness limit, and the indenture governing the notes will limit, our ability to incur additional indebtedness, these restrictions are subject to a number of qualifications and exceptions and, under certain circumstances, debt incurred in compliance with these restrictions could be substantial. If we incur substantial additional indebtedness in the future, these higher levels of indebtedness could have important consequences to you, because:

The indenture governing the notes will contain certain covenants that limit our operating flexibility.

        The indenture governing the notes will contain certain covenants that, among other things, will restrict our, our guarantor's, and our subsidiaries' ability to take specific actions, even if we believe them to be in our best interest, including restrictions on our ability to:

        In addition, our 4.60% unsecured senior notes payable, unsecured senior line of credit, 2016 unsecured senior bank term loan, and 2017 unsecured senior bank term loan require us to meet specified financial ratios and the indenture governing the notes will require us to maintain at all times a specified ratio of unencumbered assets to unsecured debt. These covenants may restrict our ability to expand or fully pursue our business strategies. Our ability to comply with these and other provisions of the indenture governing the notes and our existing 4.60% unsecured senior notes payable, unsecured senior line of credit, 2016 unsecured senior bank term loan, and 2017 unsecured senior bank term loan may be affected by changes in our operating and financial performance, changes in general business and economic conditions, adverse regulatory developments or other events beyond our control. The breach of any of these covenants, including those contained in our unsecured senior line of credit and the indenture governing the notes, could result in a default under our indebtedness, which could cause those and other obligations to become due and payable. If any of our indebtedness is accelerated, we may not be able to repay it.

If an active and liquid trading market for the notes does not develop, the market price of the notes may decline and you may be unable to sell your notes.

        The notes are a new issue of securities for which there is currently no public market. We do not intend to list the notes on any national securities exchange or for a quotation of the notes on any quotation system. Accordingly, an active trading market may not develop for the notes. Even if a trading market for the notes develops, the market may not be liquid. If an active trading market does

S-12


Table of Contents

not develop, you may be unable to resell your notes or may only be able to sell them at a substantial discount.

We may invest or spend the net proceeds in this offering in ways with which you may not agree and in ways that may not earn a profit.

        We intend to use the net proceeds from this offering to prepay $150 million of the outstanding principal balance of our 2016 unsecured senior bank term loan, to reduce the outstanding balance on our unsecured senior line of credit to zero, and to hold the remaining proceeds in cash and cash equivalents to fund near term opportunities related to development/redevelopment projects, to fund near term property acquisitions, and for general corporate purposes. After reducing the outstanding balance of our unsecured senior line of credit to zero, the Company may also borrow from time to time under such line of credit for any of the foregoing purposes. However, we will retain broad discretion over the use of the proceeds from this offering. You may not agree with the ways we decide to use these proceeds, and our use of the proceeds may not yield any profits.

We may redeem your notes at our option, which may adversely affect your return.

        As described under "Description of Notes and Guarantee—Our Redemption Rights," we have the right to redeem the notes in whole or in part from time to time. We may choose to exercise this redemption right when prevailing interest rates are relatively low. As a result, you may not be able to reinvest the redemption proceeds in a comparable security at an effective interest rate as high as that of the notes.

An increase in market interest rates could result in a decrease in the value of the notes.

        In general, as market interest rates rise, notes bearing interest at a fixed rate generally decline in value because the premium, if any, over market interest rates will decline. Consequently, if you purchase the notes and market interest rates increase, the market value of your notes may decline. We cannot predict the future level of market interest rates.

Adverse changes in our credit ratings could negatively affect our financing ability.

        Our credit ratings may affect the amount of capital we can access, as well as the terms and pricing of any debt we may incur. There can be no assurance that we will be able to maintain our current credit ratings. In the event that our current credit ratings are downgraded or removed, we would most likely incur higher borrowing costs and experience greater difficulty in obtaining additional financing, which would in turn have a material adverse impact on our financial condition, results of operations, and liquidity.

S-13


Table of Contents


ALEXANDRIA REAL ESTATE EQUITIES, INC.

General

        We are a Maryland corporation formed in October 1994 that has elected to be taxed as a REIT for federal income tax purposes. We are the largest and leading REIT focused principally on owning, operating, developing, redeveloping, and acquiring high-quality, sustainable real estate for the broad and diverse life science industry. Founded in 1994, we are the first REIT to identify and pursue the laboratory niche and have since had the first-mover advantage in the core life science cluster locations including Greater Boston, San Francisco Bay Area, San Diego, New York City, Seattle, Suburban Washington, D.C., and Research Triangle Park. Our high-credit client tenants span the life science industry, including renowned academic and medical institutions, multinational pharmaceutical companies, public and private biotechnology entities, U.S. government research agencies, medical device companies, industrial biotech companies, venture capital firms, and life science product and service companies.

        As of March 31, 2013, we had 173 properties aggregating 16.7 million RSF, composed of approximately 14.2 million RSF of operating properties, approximately 2.1 million RSF undergoing active development, and approximately 0.4 million RSF undergoing active redevelopment. Our operating properties were approximately 93.0% leased as of March 31, 2013. Our primary sources of revenues are rental income and tenant recoveries from leases of our properties. Investment-grade client tenants represented 46% of our total annualized base rent as of March 31, 2013. The comparability of financial data from period to period is affected by the timing of our property acquisition, development, and redevelopment activities.

Business Objectives and Strategies

        Our primary business objective is to maximize stockholder value by providing our stockholders with the greatest possible total return and long-term asset value based on a multifaceted platform of internal and external growth. The key elements to our strategy include our consistent focus on high-quality assets and operations in the top life science cluster locations with our properties located in close proximity to life science entities, driving growth and technological advances within each cluster. These locations are characterized by high barriers to entry for new landlords, high barriers to exit for client tenants and limited supply of available space. They represent highly desirable locations for tenancy by life science entities because of the close proximity to concentrations of specialized skills, knowledge, institutions, and related businesses. Our strategy also includes drawing upon our deep and broad life science and real estate relationships in order to attract new and leading life science client tenants and value-added real estate.

        We focus our property operations and investment activities principally in key life science markets, including Greater Boston, San Francisco Bay Area, San Diego, Greater NYC, Suburban Washington, D.C., Seattle, and Research Triangle Park.

        Our client tenant base is broad and diverse within the life science industry and reflects our focus on regional, national, and international client tenants with substantial financial and operational resources. For a more detailed description of our properties and client tenants, see "Properties." We have an experienced board of directors and are led by a senior management team with extensive experience in both the real estate and life science industries.

2013 Highlights

Core Operations

        The key elements to our strategy include our consistent focus on high-quality assets and operations in the top life science cluster locations; our properties are located adjacent to life science entities,

S-14


Table of Contents

driving growth and technological advances within each cluster. These adjacency locations are characterized by high barriers to entry for new landlords, high barriers to exit for client tenants, and limited supply of available space. They represent highly desirable locations for tenancy by life science entities because of the close proximity to concentrations of specialized skills, knowledge, institutions, and related businesses. Our strategy also includes drawing upon our deep and longstanding life science and real estate relationships in order to attract new and leading life science client tenants that provide us with our unique ability to create value through strong tenant retention and strategic development and redevelopment projects.

        The following table presents information regarding our asset base and value-added projects as of March 31, 2013, and December 31, 2012:

Rentable square feet
  March 31,
2013
  December 31,
2012
 

Operating properties

    14,168,626     14,992,086  

Development properties

    2,060,299     1,566,774  

Redevelopment properties

    430,523     547,092  
           

Total rentable square feet

    16,659,448     17,105,952  
           

Number of properties

    173     178  

Occupancy of operating properties

    93.0 %   93.4 %

Occupancy of operating and redevelopment properties

    90.1 %   89.8 %

Annualized base rent per leased rentable square foot

  $ 34.92   $ 34.59  

Leasing

        For the three months ended March 31, 2013, we executed a total of 44 leases for approximately 703,000 RSF at 29 different properties (excluding month-to-month leases). Of this total, approximately 156,000 RSF related to new or renewal leases of previously leased space (renewed/re-leased space), and approximately 547,000 RSF related to developed, redeveloped, or previously vacant space. Of the 547,000 RSF, approximately 457,000 RSF related to our development or redevelopment projects, and the remaining approximately 90,000 RSF related to previously vacant space. Rental rates for renewed/re-leased spaces were, on average, approximately 5.9% higher on a cash basis and approximately 12.7% higher on a GAAP basis than rental rates for the respective expiring leases. Additionally, we granted tenant concessions, including free rent averaging approximately 1.2 months, with respect to the 703,000 RSF leased during the three months ended March 31, 2013. Approximately 65.9% of the number of leases executed during the three months ended March 31, 2013, did not include concessions for free rent. The weighted average lease term based on leased square feet for the leases executed during the three months ended March 31, 2013, was 8.7 years.

        As of March 31, 2013, approximately 94% of our leases (on a RSF basis) were triple net leases, requiring client tenants to pay substantially all real estate taxes, insurance, utilities, common area expenses, and other operating expenses (including increases thereto) in addition to base rent. Additionally, approximately 96% of our leases (on a RSF basis) contained effective annual rent escalations that were either fixed or indexed based on a consumer price index or another index, and approximately 92% of our leases (on a RSF basis) provided for the recapture of certain capital expenditures.

S-15


Table of Contents

        The following table summarizes our leasing activity at our properties:

 
  Three
Months Ended
  Twelve
Months Ended
  Year Ended  
 
  March 31, 2013   March 31, 2013   December 31, 2012   December 31, 2011   December 31, 2010  
 
  Cash   GAAP   Cash   GAAP   Cash   GAAP   Cash   GAAP   Cash   GAAP  

Leasing activity:

                                                             

Lease expirations

                                                             

Number of leases

    49     49     152     152     162     162     158     158     129     129  

Rentable square footage

    360,956     360,956     2,183,948     2,183,948     2,350,348     2,350,348     2,689,257     2,689,257     2,416,291     2,416,291  

Expiring rates

  $ 32.83   $ 30.21   $ 30.95   $ 28.15   $ 30.03   $ 27.65   $ 29.98   $ 28.42   $ 27.18   $ 28.54  

Renewed/re-leased space

                                                             

Number of leases

    19     19     85     85     102     102     109     109     89     89  

Leased rentable square footage

    155,881     155,881     1,356,755     1,356,755     1,475,403     1,475,403     1,821,866     1,821,866     1,777,966     1,777,966  

Expiring rates

  $ 29.70   $ 28.12   $ 31.78   $ 30.20   $ 30.47   $ 28.87   $ 30.73   $ 28.79   $ 28.84   $ 30.54  

New rates

  $ 31.45   $ 31.70   $ 31.45   $ 32.08   $ 29.86   $ 30.36   $ 30.16   $ 30.00   $ 29.41   $ 32.04  

Rental rate changes

    5.9 %   12.7 %   (1.0 )%   6.2 %   (2.0 )%(1)   5.2 %(1)   (1.9 )%   4.2 %   2.0 %   4.9 %

TI's/lease commissions per square foot

  $ 5.66   $ 5.66   $ 5.93   $ 5.93   $ 6.22   $ 6.22   $ 5.82   $ 5.82 % $ 4.40   $ 4.40  

Average lease terms

    2.6 years     2.6 years     4.7 years     4.7 years     4.7 years     4.7 years     4.2 years     4.2 years     8.1 years     8.1 years  

Developed/redeveloped/previously vacant space leased

                                                             

Number of leases

    25     25     83     83     85     85     81     81     53     53  

Rentable square footage

    547,020     547,020     1,715,316     1,715,316     1,805,693     1,805,693     1,585,610     1,585,610     966,273     966,273  

New rates

  $ 50.89   $ 52.54   $ 35.08   $ 36.30   $ 30.66   $ 32.56   $ 33.45   $ 36.00   $ 36.33   $ 39.89  

TI's/lease commissions per square foot

  $ 7.52   $ 7.52   $ 9.77   $ 9.77   $ 11.02   $ 11.02   $ 12.78   $ 12.78   $ 8.10   $ 8.10  

Average lease terms

    10.4 years     10.4 years     9.2 years     9.2 years     9.0 years     9.0 years     8.9 years     8.9 years     9.7 years     9.7 years  

Leasing activity summary:

                                                             

Totals(2)

                                                             

Number of leases

    44     44     168     168     187     187     190     190     142     142  

Rentable square footage

    702,901     702,901     3,072,071     3,072,071     3,281,096     3,281,096     3,407,476     3,407,476     2,744,239     2,744,239  

New rates

  $ 46.58   $ 47.92   $ 33.48   $ 34.44   $ 30.30   $ 31.57   $ 31.69   $ 32.79   $ 31.84   $ 34.80  

TI's/lease commissions per square foot

  $ 7.11   $ 7.11   $ 8.07   $ 8.07   $ 8.87   $ 8.87   $ 9.06   $ 9.06   $ 5.70   $ 5.70  

Average lease terms

    8.7 years     8.7 years     7.3 years     7.3 years     7.1 years     7.1 years     6.4 years     6.4 years     8.7 years     8.7 years  

(1)
Excluding one lease for 48,000 RSF in the Research Triangle Park market, and two leases for 141,000 RSF in the Suburban Washington, D.C. market, rental rates for renewed/re-leased space were, on average, 0.4% higher and 7.1% higher than rental rates for expiring leases on a cash and GAAP basis, respectively.
(2)
Excludes 14 month-to-month leases for approximately 53,946 RSF.

        During the three months ended March 31, 2013, we granted tenant concessions/free rent averaging approximately 1.2 month with respect to the 702,901 rentable square feet leased.

Lease Structure
  March 31, 2013  

Percentage of triple net leases

    94 %

Percentage of leases containing annual rent escalations

    96 %

Percentage of leases providing for the recapture of capital expenditures

    92 %

        The following chart presents our total RSF leased by development/redevelopment space leased and renewed/re-leased/previously vacant space leased:

GRAPHIC

S-16


Table of Contents

Development, Redevelopment, and Future Value-Added Projects

        A key component of our business model is our value-added development and redevelopment projects. These programs are focused on providing high-quality, generic, and reusable life science laboratory space to meet the real estate requirements of a wide range of clients in the life science industry. Upon completion, each value-added project is expected to generate significant revenues and cash flows. Our development and redevelopment projects are generally in locations that are highly desirable to life science entities, which we believe results in higher occupancy levels, longer lease terms, and higher rental income and returns.

        Development projects generally consist of the ground-up development of generic and reusable life science laboratory facilities. Redevelopment projects generally consist of the permanent change in use of office, warehouse, and shell space into generic life science laboratory space. We anticipate execution of new active development projects for aboveground vertical construction of new life science laboratory space generally with significant pre-leasing. Preconstruction activities include entitlements, permitting, design, site work, and other activities prior to commencement of vertical construction of aboveground shell and core improvements. Our objective also includes the advancement of preconstruction efforts to reduce the time required to deliver projects to prospective client tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of buildings. Ultimately, these projects will provide high-quality facilities for the life science industry and are expected to generate significant revenue and cash flows for the Company.

        As of March 31, 2013, we had six ground-up development projects in process, including an unconsolidated joint venture development project, aggregating approximately 1,854,859 RSF in North America. We also had seven projects undergoing conversion into laboratory space through redevelopment, aggregating approximately 331,380 RSF in North America. These projects, along with recently delivered projects, certain future projects, and contribution from same properties, are expected to contribute significant increases in rental income, NOI, and cash flows.

S-17


Table of Contents

        Our investments in real estate, net, consisted of the following as of March 31, 2013 (dollars in thousands):

 
  March 31, 2013  
 
  Book Value   Square Feet  

Rental properties:

             

Land (related to rental properties)

  $ 516,957        

Buildings and building improvements

    4,955,207        

Other improvements

    163,864        
             

Rental properties

    5,636,028     14,168,626  

Less: accumulated depreciation

    (849,891 )      
             

Rental properties, net

    4,786,137        

Construction in progress ("CIP")/current value-added projects:

             

Active development in North America

    579,273     1,441,323  

Investment in unconsolidated real estate entity

    30,730     413,536  

Active redevelopment in North America

    141,470     331,380  

Generic infrastructure/building improvement projects in North America

    62,869        

Active development and redevelopment in Asia

    101,357     718,119  
           

    915,699     2,904,358  
           

Subtotal

    5,701,836     17,072,984  

Land/future value-added projects:

             

Land subject to sale negotiations

    45,378     399,888  

Land undergoing preconstruction activities (additional CIP) in North America          

    305,300     2,017,667  

Land held for future development in North America

    238,933     3,692,181  

Land held for future development/land undergoing preconstruction activities (additional CIP) in Asia

    83,735     6,828,864  
           

    673,346     12,938,600  
           

Investments in real estate, net

  $ 6,375,182     30,011,584  
           

        As of March 31, 2013, our active development and redevelopment projects represent 13% of gross investments in real estate, a significant amount of which is pre-leased and expected to be primarily delivered over the next one to eight quarters. Land undergoing preconstruction activities represents 5% of gross investment in real estate. The largest project primarily included in land undergoing preconstruction consists of our 1.2 million developable square feet at Alexandria Center™ at Kendall Square in East Cambridge, Massachusetts. Land held for future development represent 4% of our non-income-producing assets. Over the next few years, we may also identify certain land parcels for potential sale. Non-income-producing assets as a percentage of our gross investments in real estate is targeted to decrease to a range from 15% to 17% by December 31, 2013, and targeted to be 15% or less for the subsequent periods.

S-18


Table of Contents

        The chart below shows the historical trend of non-income-producing assets as a percentage of our gross investments in real estate:

GRAPHIC

        The following table presents our updated construction spending projections reflecting re-evaluation of the decision to execute a partial sale of our 75/125 Binney development project. This re-evaluation will result in increases in construction spending of approximately $47 million for the remainder of 2013 and $163 million thereafter.

Construction spending-projection
  Nine Months Ended
December 31, 2013
(in thousands)
  Thereafter
(in thousands)
 

Active development projects in North America

  $ 309,809   $ 326,367 (1)

Active redevelopment projects in North America

    62,335     14,043  

Preconstruction

    33,760     TBD (2)

Generic infrastructure/building improvement projects in North America(3)

    36,728     TBD (2)

Future projected construction projects(4)

    42,320 - 92,320     TBD (2)

Development and redevelopment projects in Asia

    27,799     23,154  
           

Total construction spending

  $ 512,751 - 562,751   $ 363,564  
           

(1)
Approximately 60% of construction spending beyond December 31, 2013 is expected to be funded by future secured construction loan borrowings related to our 269 East Grand Avenue and 75/125 Binney Street development projects.
(2)
Estimated spending beyond 2013 will be determined at a future date and is contingent upon many factors.
(3)
Includes, among others, generic infrastructure building improvement projects in North America, including 215 First Street, 7030 Kit Creek, and 1300 Quince Orchard Boulevard.
(4)
Includes future projected construction projects in North America, including 3013/3033 Science Park Road.

S-19


Table of Contents

        The following tables provide detail on all of our active development projects in North America as of March 31, 2013 (dollars in thousands, except per RSF amounts):

 
   
   
  Leased Status RSF(1)    
 
  Project RSF(1)    
 
   
   
   
   
  % Leased/
Negotiating
   
Property/Market—Submarket
  CIP   Total   Leased   Negotiating   Marketing   Total   Client Tenants

All active development projects in North America

                                             

Consolidated development projects in North America

                                             

225 Binney Street/Greater Boston—Cambridge

    305,212     305,212     305,212             305,212     100 % Biogen Idec Inc.

499 Illinois Street/San Francisco Bay Area—Mission Bay

    222,780     222,780         162,549     60,231     222,780     73 % TBA

269 East Grand Avenue/San Francisco Bay Area—South San Francisco

    107,250     107,250     107,250             107,250     100 % Onyx Pharmaceuticals, Inc.

430 East 29th Street/Greater NYC—Manhattan

    419,806     419,806     60,816     152,488 (2)   206,502     419,806     51 % Roche/TBA

75/125 Binney Street/Greater Boston—Cambridge

    386,275     386,275     244,123         142,152 (3)   386,275     63 % ARIAD Pharmaceuticals, Inc.
                                 

Consolidated development projects in North America

    1,441,323     1,441,323     717,401     315,037     408,885     1,441,323     72 %  

Unconsolidated joint venture

                                             

360 Longwood Avenue/Greater Boston—Longwood

    413,536     413,536     154,100         259,436     413,536     37 % Dana-Farber Cancer Institute, Inc.
                                 

Total

    1,854,859     1,854,859     871,501     315,037     668,321     1,854,859     64 %  
                                 

 

 
  Investment(1)    
   
   
   
   
 
 
  Initial
Stabilized
Yield(1)
   
   
   
 
 
   
  Cost To Complete    
   
   
   
   
 
 
   
  Total at
Completion
  Cost
Per
RSF
  Projected
Start
Date(1)
  Occupancy
Date(1)
  Initial
Stabilization
Date(1)
 
Property/Market—Submarket
  CIP   2013   Thereafter   Cash   GAAP  

All active development projects in North America

                                                             

Consolidated development projects in North America

                                                             

225 Binney Street/Greater Boston—Cambridge

  $ 118,595   $ 61,678   $   $ 180,273   $ 591     7.5 %   8.1 %   4Q11     4Q13     4Q13  

499 Illinois Street/San Francisco Bay Area—Mission Bay

  $ 116,110   $ 14,298   $ 22,801   $ 153,209   $ 688     6.4 %   7.2 %   2Q11     2Q14     2014  

269 East Grand Avenue/San Francisco Bay Area—South San Francisco(4)

  $ 8,037   $ 13,100   $ 30,163   $ 51,300   $ 478     8.1 %   9.3 %   1Q13     4Q14     2014  

430 East 29th Street/Greater NYC—Manhattan

  $ 239,086   $ 113,879   $ 110,280   $ 463,245   $ 1,103     6.6 %   6.5 %   4Q12     4Q13     2015  

75/125 Binney Street/Greater Boston—Cambridge(5)

  $ 97,445   $ 90,871   $ 163,123   $ 351,439   $ 910     8.0 %   8.2 %   1Q13     1Q15     2015  
                                                       

Consolidated development projects in North America

  $ 579,273   $ 293,826   $ 326,367   $ 1,199,466                                      

Unconsolidated joint venture

                                                             

360 Longwood Avenue/Greater Boston—Longwood

  $ 148,596   $ 67,744   $ 133,660   $ 350,000   $ 846     8.3 %   8.9 %   2Q12     4Q14     2016  

JV partner capital/JV construction loan

  $ (123,638 ) $ (51,761 ) $ (133,660 ) $ (309,059 )                                    
                                                       

ARE investment in 360 Longwood Avenue (27.5% ownership interest)

  $ 24,958   $ 15,983   $   $ 40,941                                      
                                                       

Total

  $ 604,231   $ 309,809   $ 326,367   $ 1,240,407                                      
                                                       

(1)
All project information, including RSF; investment; Initial Stabilized Yields; and project start, occupancy and stabilization dates, relate to the discrete portion of each property undergoing active development or redevelopment. A redevelopment project does not necessarily represent the entire property or the entire vacant portion of a property. Our Initial Stabilized Yield on a cash basis reflects cash rents at date of stabilization and does not reflect contractual rent escalations beyond the stabilization date. Our cash rents related to our value-added projects are expected to increase over time and our average stabilized cash yields are expected, in general, to be greater than our Initial Stabilized Yields. Our estimates for initial cash and GAAP yields, and total costs at completion, represent our initial estimates at the commencement of the project. We expect to update this information upon completion of the project, or sooner if there are significant changes to the expected project yields or costs. As of March 31, 2013, 96% of our leases contained annual rent escalations that were either fixed or based on a consumer price index or another index.
(2)
Represents 131,000 RSF subject to an executed letter of intent with the remainder subject to letters of intent or lease negotiations.
(3)
ARIAD Pharmaceuticals, Inc. has potential additional expansion opportunities at 75 Binney Street through June 2014.
(4)
Funding for 70% of the estimated total investment at completion for 269 East Grand Avenue is expected to be provided primarily by a secured construction loan.
(5)
Funding for 60% to 70% of the estimated total project costs is expected to be provided by a secured construction loan.

S-20


Table of Contents

        The following tables provide detail on all of our active redevelopment projects in North America as of March 31, 2013 (dollars in thousands, except per RSF amounts):

 
  Project RSF(1)   Leased Status RSF(1)    
   
   
Property/Market—
Submarket
  In
Service
  CIP   Total   Leased   Negotiating   Marketing   Total   % Leased/
Negotiating
  Former
Use
  Use After
Conversion
  Client Tenants

All active redevelopment projects in North America

                                                           

400 Technology Square/Greater Boston—Cambridge
 

    162,153     49,971     212,124     169,939         42,185     212,124     80 % Office   Laboratory   Ragon Institute of MGH, MIT and Harvard; Epizyme, Inc.; Warp Drive Bio, LLC; Aramco Services Company, Inc.

285 Bear Hill Road/Greater Boston—Route 128

        26,270     26,270     26,270             26,270     100 % Office/
Manufacturing
  Laboratory   Intelligent Medical Devices, Inc.

343 Oyster Point/San Francisco Bay Area—South San Francisco

        53,980     53,980     42,445         11,535     53,980     79 % Office   Laboratory   Calithera BioSciences, Inc.; CytomX Therapeutics, Inc.

4757 Nexus Center Drive/San Diego—University Town Center

        68,423     68,423     68,423             68,423     100 % Manufacturing/
Warehouse/Office/
R&D
  Laboratory   Genomatica, Inc.

9800 Medical Center Drive/Suburban Washington, D.C.—Rockville

    8,001     67,055     75,056     75,056             75,056     100 % Office/Laboratory   Laboratory   National Institutes of Health

1551 Eastlake Avenue/Seattle—Lake Union

    77,821     39,661     117,482     77,821         39,661     117,482     66 % Office   Laboratory   Puget Sound Blood Center and Program

1616 Eastlake Avenue/Seattle—Lake Union

    40,756     26,020     66,776     40,756         26,020     66,776     61 % Office   Laboratory   Infectious Disease Research Institute
                                             

Total

    288,731     331,380     620,111     500,710         119,401     620,111     81 %          
                                             

 

 
  Investment(1)    
   
   
   
   
 
 
  Initial
Stabilized
Yield(1)
   
   
   
 
 
  March 31, 2013   To Complete    
   
   
   
   
 
 
  Total at
Completion
  Cost Per
RSF
  Project
Start
Date(1)
  Initial
Occupancy
Date(1)
  Stabilization
Date(1)
 
Property/Market—Submarket
  In Service   CIP   2013   Thereafter   Cash   GAAP  

All active redevelopment projects in North America

                                                                   

400 Technology Square/Greater Boston—Cambridge

  $ 99,980   $ 32,212   $ 9,176   $ 3,320   $ 144,688   $ 682     8.1 %   8.9 %   4Q11     4Q12     4Q13  

285 Bear Hill Road/Greater Boston—Route 128

  $   $ 4,654   $ 4,542   $   $ 9,196   $ 350     8.4 %   8.8 %   4Q11     3Q13     2013  

343 Oyster Point/San Francisco Bay Area—South San Francisco

  $   $ 10,912   $ 5,560   $ 867   $ 17,339   $ 321     9.6 %   9.8 %   1Q12     3Q13     2014  

4757 Nexus Center Drive/San Diego—University Town Center

  $   $ 5,879   $ 23,747   $ 5,203   $ 34,829   $ 509     7.6 %   7.8 %   4Q12     4Q13     4Q13 (2)

9800 Medical Center Drive/Suburban Washington, D.C.—Rockville

  $ 7,454   $ 61,251   $ 11,999   $   $ 80,704     (3)     5.4 %   5.4 %   3Q09     1Q13     2013  

1551 Eastlake Avenue/Seattle—Lake Union

  $ 40,711   $ 16,841   $ 6,458   $   $ 64,010   $ 545     6.7 %   6.7 %   4Q11     4Q11     4Q13  

1616 Eastlake Avenue/Seattle—Lake Union

  $ 22,589   $ 9,721   $ 853   $ 4,653   $ 37,816   $ 566     8.4 %   8.6 %   4Q12     2Q13     2014  
                                                           

Total

  $ 170,734   $ 141,470   $ 62,335   $ 14,043   $ 388,582                                      
                                                           

(1)
All project information, including RSF; investment; Initial Stabilized Yields; and project start, occupancy and stabilization dates, relates to the discrete portion of each property undergoing active development or redevelopment. A redevelopment project does not necessarily represent the entire property or the entire vacant portion of a property. Our Initial Stabilized Yield on a cash basis reflects cash rents at date of stabilization and does not reflect contractual rent escalations beyond the stabilization date. Our cash rents related to our value-added projects are expected to increase over time and our average stabilized cash yields are expected, in general, to be greater than our Initial Stabilized Yields. Our estimates for initial cash and GAAP yields, and total costs at completion, represent our initial estimates at the commencement of the project. We expect to update this information upon completion of the project, or sooner if there are significant changes to the expected project yields or costs. As of March 31, 2013, 96% of our leases contained annual rent escalations that were either fixed or based on a consumer price index or another index.
(2)
We expect to deliver 54,102 RSF, or 79% of the total project, to Genomatica, Inc. in the fourth quarter of 2013. Genomatica, Inc. is contractually required to lease the remaining 14,411 RSF 18 to 24 months following the delivery of the initial 54,102 RSF space.
(3)
Our multi-tenant four building property at 9800 Medical Center Drive contains an aggregate of 281,586 RSF. Our total cash investment in the entire four building property upon completion of the redevelopment will approximate $580 per square foot. Our total expected cash investment for the four building property of approximately $580 per square foot includes our expected total investment at completion related to the 75,056 RSF redevelopment of approximately $1,075 per square foot.

S-21


Table of Contents

        The following table summarizes the components of the square footage of our future value-added projects in North America as of March 31, 2013 (dollars in thousands, except per square foot amounts):

 
  Land Undergoing
Preconstruction
Activities (Additional CIP)(1)
  Land Held for Future
Development(1)
  Total(1)  
Property/Market—Submarket
  Book
Value
  Square
Feet(2)
  Cost per
Square Foot
  Book
Value
  Square
Feet(2)
  Cost per
Square Foot
  Book
Value
  Square
Feet(2)
  Cost per
Square Foot
 

Greater Boston:

                                                       

Alexandria Center at Kendall Square—Residential—Cambridge/Inner Suburbs

  $ 1,582     78,000   $ 20   $ 3,413     150,000   $ 23   $ 4,995     228,000   $ 22  

Alexandria Center at Kendall Square—Lab/Office—Cambridge/Inner Suburbs

    251,874     974,264     259                 251,874     974,264     259  
                                       

Subtotal—Alexandria Center at Kendall Square

    253,456     1,052,264     241     3,413     150,000     23     256,869     1,202,264     214  

Technology Square—Cambridge/Inner Suburbs

                7,803     100,000     78     7,803     100,000     78  
                                       

Greater Boston

  $ 253,456     1,052,264   $ 241   $ 11,216     250,000   $ 45   $ 264,672     1,302,264   $ 203  

San Francisco Bay Area:

                                                       

Owens Street—Mission Bay

  $       $   $ 27,762     290,059   $ 96   $ 27,762     290,059   $ 96  

Grand Ave—South San Francisco

                42,853     397,132     108     42,853     397,132     108  

Rozzi/Eccles—South San Francisco

                72,879     514,307     142     72,879     514,307     142  
                                       

San Francisco Bay Area

  $       $   $ 143,494     1,201,498   $ 119   $ 143,494     1,201,498   $ 119  

San Diego:

                                                       

Science Park Road—Torrey Pines

  $ 16,298     176,500   $ 92   $       $   $ 16,298     176,500   $ 92  

5200 Illumina Way—University Town Center

    14,298     392,983     36                 14,298     392,983     36  

10300 Campus Point—University Town Center

    3,857     140,000     28                 3,857     140,000     28  

Executive Drive—University Town Center

    3,919     49,920     79                 3,919     49,920     78  
                                       

San Diego

  $ 38,372     759,403   $ 51   $       $   $ 38,372     759,403   $ 51  

Suburban Washington D.C.:

                                                       

Medical Center Drive—Rockville

  $       $   $ 7,548     292,000   $ 26   $ 7,548     292,000   $ 26  

Research Boulevard—Rockville

                6,698     347,000     19     6,698     347,000     19  

Firstfield Road—Gaithersburg

                4,052     95,000     43     4,052     95,000     43  

Freedom Center Drive and Pyramid Place—Virginia

                11,791     424,905     28     11,791     424,905     28  
                                       

Suburban Washington D.C. 

  $       $   $ 30,089     1,158,905   $ 26   $ 30,089     1,158,905   $ 26  

Seattle:

                                                       

Dexter/Terry Ave—Lake Union

  $       $   $ 18,747     232,300   $ 81   $ 18,747     232,300   $ 81  

Eastlake Ave—Lake Union

    13,472     106,000     127     15,241     160,266     95     28,713     266,266     108  
                                       

Seattle

  $ 13,472     106,000   $ 127   $ 33,988     392,566   $ 87   $ 47,460     498,566   $ 95  

Other Markets

  $       $   $ 20,146     789,212   $ 26   $ 20,146     789,212   $ 26  
                                       

Future value-added projects in North America

  $ 305,300     1,917,667   $ 159   $ 238,933     3,792,181   $ 63   $ 544,233     5,709,848   $ 95  
                                       

(1)
In addition to assets included in our gross investment in real estate, we hold options/rights for parcels supporting the future ground-up development of approximately 420,000 RSF in Alexandria CenterTM for Life Science—New York City related to an option under our ground lease. Also, our asset base contains additional embedded development opportunities aggregating approximately 644,000 RSF which represents additional development and expansion rights related to existing rental properties. The 644,000 RSF related to these additional development opportunities was previously included in land held for future development.
(2)
Square feet amounts are updated as necessary to reflect refinement of design of each building.

S-22


Table of Contents

        The following table summarizes the components of the square footage of our future redevelopment projects in North America as of March 31, 2013:

Market—Submarket
  Future
Redevelopment
Square Feet(1)
 

Greater Boston

    109,457  

San Francisco Bay Area—South San Francisco

    40,314  

San Diego

    87,488  

Suburban Washington, D.C. 

    490,000  

Seattle

    14,914  

Other markets

    94,211  
       

Total future redevelopment in North America

    836,384  
       

(1)
Our asset base also includes non-laboratory space (office, warehouse, and industrial space) identified for future conversion into life science laboratory space through redevelopment. These spaces are classified in investments in real estate, net, in the condensed consolidated balance sheets.

        As of March 31, 2013, our rental properties, net, in Asia, consisted of five operating properties aggregating approximately 603,987 square feet, with occupancy of 67.1%. Annualized base rent of our operating properties in Asia was approximately $4.3 million as of March 31, 2013. Our primary sources of revenues are rental income and tenant recoveries from leases of our properties.

        We also had construction projects in Asia aggregating approximately 718,119 and 734,444 RSF as of March 31, 2013, and December 31, 2012, respectively.

        Our investments in real estate, net, in Asia, consisted of the following as of March 31, 2013 (dollars in thousands, except per square foot amounts):

 
  March 31, 2013  
 
  Book Value   Square Feet   Cost per
Square Foot
 

Rental properties, net, in China

  $ 21,352     299,484   $ 71  

Rental properties, net, in India

    35,337     304,503     116  

CIP/current value-added projects:

                   

Active development in China

    58,500     309,476     189  

Active development in India

    29,713     309,500     96  

Active redevelopment projects in India

    13,144     99,143     133  
               

    101,357     718,119     141  

Land held for future development/land undergoing preconstruction activities (additional CIP)—India

    83,735     6,829,000     12  
               

Total investments in real estate, net, in Asia

  $ 241,781     8,151,106   $ 30  
               

Liquidity and Capital Resources

        Recent Events:

S-23


Table of Contents

        We expect to meet certain long-term liquidity requirements, such as requirements for property acquisitions, development, redevelopment, other construction projects, capital improvements, tenant improvements, leasing costs, non-revenue-generating expenditures, and scheduled debt maturities, through net cash provided by operating activities, periodic asset sales, and long-term secured and unsecured indebtedness, including borrowings under our unsecured senior line of credit, unsecured senior bank term loans, and the issuance of additional debt and/or equity securities.

        We expect to continue meeting our short-term liquidity and capital requirements, as further detailed in this section, generally through our working capital and net cash provided by operating activities. We believe that the net cash provided by operating activities will continue to be sufficient to enable us to make the distributions necessary to continue qualifying as a REIT.

        Over the next several years, our balance sheet, capital structure, and liquidity objectives are as follows:

S-24


Table of Contents


PROPERTIES

General

        As of March 31, 2013, we had 173 properties containing approximately 16.7 million RSF of life science laboratory space. Our operating properties were approximately 93.0% leased as of March 31, 2013. The exteriors of our properties typically resemble traditional office properties, but the interior infrastructures are designed to accommodate the needs of life science industry client tenants. These improvements typically are generic to life science industry client tenants rather than being specific to a particular client tenant. As a result, we believe that the improvements have long-term value and utility and are usable by a wide range of life science industry client tenants. Laboratory improvements to our life science properties typically include:

        As of March 31, 2013:

        Our leases also typically give us the right to review and approve tenant alterations to the property. Generally, tenant-installed improvements to the properties are reusable generic life science laboratory improvements and remain our property after termination of the lease at our election. However, we are permitted under the terms of most of our leases to require that the client tenant, at its expense, remove certain non-generic improvements and restore the premises to their original condition.

S-25


Table of Contents

Location of Properties

        The locations of our properties are diversified among a number of life science cluster markets. The following table sets forth, as of March 31, 2013, the total RSF and annualized base rent of our properties in each of our existing markets (dollars in thousands):

 
  Rentable Square Feet    
   
   
 
 
  Number of
Properties
  Annualized
Base Rent(1)
 
Market
  Operating   Development   Redevelopment   Total   % Total  

Greater Boston

    3,043,048     691,487     76,241     3,810,776     23 %   36   $ 118,060     27 %

San Francisco Bay Area

    2,486,751     330,030     53,980     2,870,761     17     26     93,816     22  

San Diego

    2,575,121         68,423     2,643,544     16     33     83,636     20  

Greater NYC

    494,656     419,806         914,462     5     6     31,844     7  

Suburban Washington, D.C. 

    2,086,468         67,055     2,153,523     13     29     43,172     10  

Seattle

    680,835         65,681     746,516     4     10     28,346     7  

Research Triangle Park

    941,807             941,807     6     14     18,852     4  

Canada

    1,103,507             1,103,507     7     5     9,258     2  

Non-cluster markets

    61,002             61,002         2     611      
                                   

North America

    13,473,195     1,441,323     331,380     15,245,898     91     161     427,595     99  

Asia

    603,987     618,976     99,143     1,322,106     8     9     4,337     1  
                                   

Continuing operations

    14,077,182     2,060,299     430,523     16,568,004     99     170     431,932     100 %
                                                 

Discontinued operations

    91,444             91,444     1     3     1,138        
                                     

Total

    14,168,626     2,060,299     430,523     16,659,448     100 %   173   $ 433,070        
                                     

(1)
Annualized base rent means the annualized fixed base rental amount in effect as of March 31, 2013 (using rental revenue computed on a straight-line basis in accordance with GAAP). Represents annualized base rent related to our operating rentable square feet.

Client Tenants

        Our life science properties are leased to a diverse group of client tenants, with no client tenant accounting for more than 7.1% of our annualized base rent. The following table sets forth information

S-26


Table of Contents

regarding leases with our 20 largest client tenants based upon annualized base rent as of March 31, 2013 (dollars in thousands):

 
   
   
  Remaining
Lease
Term in
Years
   
   
   
   
  Investment-Grade
Client Tenants(3)
   
 
 
   
   
  Approximate
Aggregate
Rentable
Square Feet
  Percentage of
Aggregate
Total
Square Feet
   
  Percentage of
Aggregate
Annualized
Base Rent
   
 
 
   
  Number
of Leases
  Annualized
Base Rent
  Fitch
Rating
  Moody's
Rating
  S&P
Rating
  Education/
Research
 
 
 
Client Tenant
  (1)   (2)  

1

 

Novartis AG

    11     3.8     3.9     612,424     3.7 % $ 30,515     7.1 % AA   Aa2   AA-      

2

 

Illumina, Inc. 

    1     18.6     18.6     497,078     3.0     19,531     4.5            

3

 

Bristol-Myers Squibb Company

    6     4.6     4.9     419,624     2.5     15,840     3.7   A   A2   A+      

4

 

Eli Lilly and Company

    5     8.3     9.9     262,182     1.6     15,068     3.5   A   A2   AA-      

5

 

FibroGen, Inc. 

    1     10.6     10.6     234,249     1.4     14,197     3.3            

6

 

Roche

    3     5.0     5.1     348,918     2.1     13,867     3.2   AA-   A1   AA      

7

 

United States Government

    9     4.0     5.0     332,578     2.0     13,103     3.0   AAA   Aaa   AA+      

8

 

GlaxoSmithKline plc

    5     6.7     6.4     208,394     1.2     10,232     2.4   A+   A1   A+      

9

 

Celgene Corporation

    3     8.4     8.3     250,586     1.5     9,340     2.2     Baa2   BBB+      

10

 

Massachusetts Institute of Technology

    4     4.2     4.4     185,403     1.1     8,499     2.0     Aaa   AAA     ü  

11

 

Onyx Pharmaceuticals, Inc. 

    2     10.1     10.1     228,373     1.4     8,498     2.0            

12

 

NYU-Neuroscience Translational Research Institute

    2     11.9     10.8     86,756     0.5     8,012     1.8   A-   A3   AA-     ü  

13

 

The Regents of the University of California

    3     8.4     8.4     188,654     1.1     7,787     1.8   AA   Aa1   AA     ü  

14

 

Alnylam Pharmaceuticals, Inc. 

    1     3.5     3.5     129,424     0.8     6,081     1.4            

15

 

Gilead Sciences, Inc. 

    1     7.3     7.3     109,969     0.7     5,824     1.3     Baa1   A-      

16

 

Pfizer Inc. 

    2     6.2     5.9     116,518     0.7     5,502     1.3   A+   A1   AA      

17

 

The Scripps Research Institute

    2     3.7     3.6     101,475     0.6     5,200     1.2   AA-   Aa3       ü  

18

 

Theravance, Inc.(4)

    2     7.2     7.2     130,342     0.8     4,895     1.1            

19

 

Infinity Pharmaceuticals, Inc. 

    2     1.8     1.8     68,020     0.4     4,423     1.0            

20

 

Quest Diagnostics Incorporated

    1     3.8     3.8     248,186     1.5     4,341     1.0   BBB+   Baa2   BBB+      
                                                     

 

Total/weighted average top 20

    66     7.3     7.5     4,759,153     28.6 % $ 210,755     48.8 %                  
                                                     

(1)
Represents remaining lease term in years based on percentage of leased square feet.
(2)
Represents remaining lease term in years based on percentage of annualized base rent in effect as of March 31, 2013.
(3)
Ratings obtained from Fitch Ratings, Moody's Investors Service, and Standard & Poor's.
(4)
As of February 14, 2013, GlaxoSmithKline plc owned approximately 27% of the outstanding stock of Theravance, Inc.

        The chart below shows client tenant business type by annualized base rent as of March 31, 2013:

GRAPHIC

S-27


Table of Contents

Summary of Lease Expirations

        The following table summarizes information with respect to the lease expirations at our properties as of March 31, 2013:

Year of Lease Expiration
  Number of Leases
Expiring
  RSF of Expiring
Leases
  Percentage of
Aggregate Total RSF
  Annualized Base
Rent of
Expiring Leases
(per RSF)
 

2013

    63 (1)   568,189 (1)   4.1 % $ 29.30  

2014

    93     1,175,374     8.6 % $ 29.20  

2015

    75     1,385,596     10.1 % $ 32.75  

2016

    57     1,342,621     9.8 % $ 30.20  

2017

    63     1,573,451     11.5 % $ 30.58  

2018

    28     1,185,758     8.6 % $ 39.80  

2019

    22     680,031     5.0 % $ 32.85  

2020

    16     762,229     5.6 % $ 40.25  

2021

    20     799,802     5.8 % $ 37.12  

2022

    15     551,214     4.0 % $ 29.43  

Thereafter

    26     2,278,602     16.6 % $ 39.96  

(1)
Excludes 14 month-to-month leases for approximately 53,946 RSF.

        Our revenues are derived primarily from rental payments and reimbursement of operating expenses under our leases. If a tenant experiences a downturn in its business or other types of financial distress, it may be unable to make timely payments under its lease. Also, if tenants decide not to renew their leases or terminate early, we may not be able to re-lease the space. Even if tenants decide to renew or lease space, the terms of renewals or new leases, including the cost of any tenant improvements, concessions and lease commissions, may be less favorable to us than current lease terms. Consequently, we could lose the cash flow from the affected properties, which could negatively impact our business. We may have to divert cash flow generated by other properties to meet our mortgage payments, if any, or to pay other expenses related to owning the affected properties.

Non-GAAP Measures

FFO

        GAAP basis accounting for real estate assets utilizes historical cost accounting and assumes that real estate values diminish over time. In an effort to overcome the difference between real estate values and historical cost accounting for real estate assets, the Board of Governors of NAREIT established the measurement tool of FFO. Since its introduction, FFO has become a widely used non-GAAP financial measure among equity REITs. We believe that FFO is helpful to investors as an additional measure of the performance of an equity REIT. Moreover, we believe that FFO, as adjusted, is also helpful because it allows investors to compare our performance to the performance of other real estate companies between periods, and on a consistent basis, without having to account for differences caused by investment and disposition decisions, financing decisions, terms of securities, capital structures, and capital market transactions. We compute FFO in accordance with standards established by the Board of Governors of NAREIT in its NAREIT White Paper. The NAREIT White Paper defines FFO as net income (computed in accordance with GAAP), excluding gains (losses) from sales of depreciable real estate and land parcels and impairments of depreciable real estate (excluding land parcels), plus real estate related depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures. Impairments of real estate relate to decreases in the estimated fair value of real estate due to changes in general market conditions and do not necessarily reflect the operating performance of the properties during the corresponding period. Impairments of real estate represent the non-cash

S-28


Table of Contents

write-down of assets when fair value over the recoverability period is less than the carrying value. Our calculation of FFO may differ from those methodologies utilized by other equity REITs for similar performance measurements, and, accordingly, may not be comparable to those of other equity REITs. FFO should not be considered as an alternative to net income (determined in accordance with GAAP) as an indication of financial performance, or to cash flows from operating activities (determined in accordance with GAAP) as a measure of liquidity, nor are they indicative of the availability of funds for our cash needs, including funds available to make distributions.

AFFO

        AFFO is a non-GAAP financial measure that we use as a supplemental measure of our performance. We compute AFFO by adding to or deducting from FFO, as adjusted: (1) non-revenue-enhancing capital expenditures, tenant improvements, and leasing commissions (excludes development and redevelopment expenditures); (2) effects of straight-line rent and straight-line rent on ground leases; (3) capitalized income from development projects; (4) amortization of acquired above and below market leases, loan fees, and debt premiums/discounts; (5) non-cash compensation expense; and (6) allocation of AFFO attributable to unvested restricted stock awards.

        We believe that AFFO is a useful supplemental performance measure because it further adjusts to: (1) deduct certain expenditures that, although capitalized and classified in depreciation expense, do not enhance the revenue or cash flows of our properties; (2) eliminate the effect of straight-lining our rental income and capitalizing income from development projects in order to reflect the actual amount of contractual rents due in the period presented; and (3) eliminate the effect of non-cash items that are not indicative of our core operations and do not actually reduce the amount of cash generated by our operations. We believe that eliminating the effect of non-cash charges related to share-based compensation facilitates a comparison of our operations across periods and among other equity REITs without the variances caused by different valuation methodologies, the volatility of the expense (which depends on market forces outside our control), and the assumptions and the variety of award types that a company can use. We believe that AFFO provides useful information by excluding certain items that are not representative of our core operating results because such items are dependent upon historical costs or subject to judgmental valuation inputs and the timing of our decisions.

        AFFO is not intended to represent cash flow for the period, and is intended only to provide an additional measure of performance. We believe that net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders is the most directly comparable GAAP financial measure to AFFO. We believe that AFFO is a widely recognized measure of the operations of equity REITs, and presenting AFFO will enable investors to assess our performance in comparison to other equity REITs. However, other equity REITs may use different methodologies for calculating AFFO and, accordingly, our AFFO may not be comparable to AFFO calculated by other equity REITs. AFFO should not be considered as an alternative to net income (determined in accordance with GAAP) as an indication of financial performance, or to cash flows from operating activities (determined in accordance with GAAP) as a measure of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to make distributions.

        The following table presents a reconciliation of net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic, the most directly comparable financial measure calculated and presented in accordance with GAAP, to FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic, FFO attributable to Alexandria Real Estate Equities, Inc.'s common

S-29


Table of Contents

stockholders—diluted, as adjusted, and AFFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted, for the periods below (in thousands):

 
  Three Months Ended
March 31,
 
 
  2013   2012  

Net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic

  $ 22,442   $ 18,368  

Depreciation and amortization

    46,995     43,405  

Loss on sale of real estate

    340      

Impairment of real estate

         

Gain on sale of land parcel

        (1,864 )

Amount attributable to noncontrolling interests/unvested restricted stock awards:

             

Net income

    1,324     946  

FFO

    (1,064 )   (1,156 )
           

FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic

    70,037     59,699  

Assumed conversion of 8.00% Unsecured Senior Convertible Notes

    5     5  
           

FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted

    70,042     59,704  

Realized gain on equity investment primarily related to one non-tenant life science entity

         

Impairment of land parcel

         

Loss on early extinguishment of debt

        623  

Preferred stock redemption charge

        5,978  

Allocation to unvested restricted stock awards

        (53 )
           

FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted, as adjusted

    70,042     66,252  

Non-revenue-enhancing capital expenditures:

             

Building improvements

    (596 )   (210 )

Tenant improvements and leasing commissions

    (882 )   (2,019 )

Straight-line rent

    (6,198 )   (8,796 )

Straight-line rent on ground leases

    538     1,406  

Capitalized income from development projects

    22     478  

Amortization of acquired above and below market leases

    (830 )   (800 )

Amortization of loan fees

    2,386     2,643  

Amortization of debt premiums/discounts

    115     179  

Stock compensation

    3,349     3,293  

Allocation to unvested restricted stock awards

    19     31  
           

AFFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted

  $ 67,965   $ 62,457  
           

S-30


Table of Contents

        The following table presents a reconciliation of net income per share attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic, the most directly comparable financial measure calculated and presented in accordance with GAAP, to FFO per share attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic, FFO per share attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted, as adjusted, and AFFO per share attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted, for the periods below:

 
  Three Months
Ended
March 31,
 
 
  2013   2012  

Net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic

  $ 0.36   $ 0.30  

Depreciation and amortization

    0.74     0.70  

Loss on sale of real estate

         

Impairment of real estate

    0.01      

Gain on sale of land parcel

        (0.03 )

Amount attributable to noncontrolling interests/unvested restricted stock awards:

             

Net income

    0.02     0.02  

FFO

    (0.02 )   (0.02 )
           

FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—basic

    1.11     0.97  

Assumed conversion of 8.00% Unsecured Senior Convertible Notes

         
           

FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted

    1.11     0.97  

Realized gain on equity investment primarily related to one non-tenant life science entity          

         

Impairment of land parcel

         

Loss on early extinguishment of debt

        0.01  

Preferred stock redemption charge

        0.10  
           

FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted, as adjusted

    1.11     1.08  

Non-revenue-enhancing capital expenditures:

             

Building improvements

    (0.01 )    

Tenant improvements and leasing commissions

    (0.01 )   (0.03 )

Straight-line rent

    (0.10 )   (0.14 )

Straight-line rent on ground leases

    0.01     0.02  

Capitalized income from development projects

        0.01  

Amortization of acquired above and below market leases

    (0.01 )   (0.01 )

Amortization of loan fees

    0.04     0.04  

Amortization of debt premiums/discounts

         

Stock compensation

    0.05     0.05  
           

AFFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders—diluted

  $ 1.08   $ 1.02  
           

NOI

        NOI is a non-GAAP financial measure equal to income from continuing operations, the most directly comparable GAAP financial measure, plus loss (gain) on early extinguishment of debt,

S-31


Table of Contents

impairment of land parcel, depreciation and amortization, interest expense, and general and administrative expense. We believe NOI provides useful information to investors regarding our financial condition and results of operations because it reflects primarily those income and expense items that are incurred at the property level. Therefore, we believe NOI is a useful measure for evaluating the operating performance of our real estate assets. NOI on a cash basis is NOI on a GAAP basis, adjusted to exclude the effect of straight-line rent adjustments required by GAAP. We believe that NOI on a cash basis is helpful to investors as an additional measure of operating performance because it eliminates straight-line rent adjustments to rental revenue.

        Further, we believe NOI is useful to investors as a performance measure, because when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, and operating costs, providing perspective not immediately apparent from income from continuing operations. NOI excludes certain components from income from continuing operations in order to provide results that are more closely related to the results of operations of our properties. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level rather than at the property level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. Real estate impairments have been excluded in deriving NOI because we do not consider impairment losses to be property-level operating expenses. Real estate impairment losses relate to changes in the values of our assets and do not reflect the current operating performance with respect to related revenues or expenses. Our real estate impairments represent the write-down in the value of the assets to the estimated fair value less cost to sell. These impairments result from investing decisions and the deterioration in market conditions that adversely impact underlying real estate values. Our calculation of NOI also excludes charges incurred from changes in certain financing decisions, such as losses on early extinguishment of debt, as these charges often relate to the timing of corporate strategy. Property operating expenses that are included in determining NOI consist of costs that are related to our operating properties, such as utilities; repairs and maintenance; rental expense related to ground leases; contracted services, such as janitorial, engineering, and landscaping; property taxes and insurance; and property-level salaries. General and administrative expenses consist primarily of accounting and corporate compensation, corporate insurance, professional fees, office rent, and office supplies that are incurred as part of corporate office management. NOI presented by us may not be comparable to NOI reported by other equity REITs that define NOI differently. We believe that in order to facilitate a clear understanding of our operating results, NOI should be examined in conjunction with income from continuing operations as presented in our condensed consolidated statements of income. NOI should not be considered as an alternative to income from continuing operations as an indication of our performance, or as an alternative to cash flows as a measure of liquidity or a measure of our ability to make distributions.

        The following table is a reconciliation of NOI from continuing operations to income from continuing operations and NOI from discontinued operations to income from discontinued operations,

S-32


Table of Contents

the most directly comparable financial measure calculated and presented in accordance with GAAP (in thousands):

 
  Three Months Ended
March 31,
 
 
  2013   2012  

Continuing operations

             

Total revenues

  $ 150,380   $ 135,711  

Rental operations

    45,224     40,453  
           

Net operating income

    105,156     95,258  
           

Operating margins

    70 %   70 %

General and administrative

    11,648     10,357  

Interest

    18,020     16,226  

Depreciation and amortization

    46,065     41,786  

Loss on early extinguishment of debt

        623  
           

Income from continuing operations

  $ 29,423   $ 26,266  
           

Discontinued operations

             

Total revenues

  $ 3,496   $ 9,308  

Rental operations

    1,412     3,043  
           

Net operating income(1)

    2,084     6,265  
           

Operating margins

    60 %   67 %

Interest

        1  

Depreciation and amortization

    930     1,619  

Loss on sale of real estate

    340      
           

Income from discontinued operations, net

  $ 814   $ 4,645  
           

(1)
Net operating income from discontinued operations for the three months ended March 31, 2013, is comprised of $0.2 million for the three assets classified as "held for sale" as of March 31, 2013, and $1.9 million for the 6 assets sold during the three months ended March 31, 2013. Net operating income from discontinued operations for the three months ended March 31, 2012, is comprised of $0.3 million for the three assets classified as "held for sale" as of March 31, 2013, and $6.0 million for the 12 assets sold since January 1, 2012.

Same Property NOI

        As a result of changes within our total property portfolio, the financial data presented in the table in "Comparison of the Three Months Ended March 31, 2013, to the Three Months Ended March 31, 2012" shows significant changes in revenue and expenses from period to period. In order to supplement an evaluation of our results of operations over a given period, we analyze the operating performance for all properties that were fully operating for the entire periods presented (herein referred to as "Same Properties") separate from properties acquired subsequent to the first period presented, properties undergoing active development and active redevelopment, and corporate entities (legal entities performing general and administrative functions), which are excluded from same property results (herein referred to as "Non-Same Properties"). Additionally, rental revenues from lease termination fees, if any, are excluded from the results of operations of the Same Properties.

S-33


Table of Contents

        The following table reconciles same properties to total properties for the three months ended March 31, 2013:

   
  Number
of
Properties
   
  Number
of
Properties
   
  Number
of
Properties
 
  Development—active       Development—deliveries since
    January 1, 2012                   
      Development/Redevelopment—Asia   7 (1)

 

225 Binney Street

 

1

 

259 East Grand Avenue

 

1

 

 

 

 

 
  269 East Grand Avenue   1   400/450 East Jamie Court   2   Properties acquired since      
  409/499 Illinois Street   2   4755 Nexus Center Drive   1       January 1, 2012                  
  430 East 29th Street   1   5200 Illumina Way   1  
6 Davis Drive
  1  
  75/125 Binney Street   1   Canada   (2)        
                         
      6       5          

 

Redevelopment—active

 

 

 

Redevelopment—deliveries since
    January 1, 2012                        

 

 

 

Properties held for sale

 

3

 
                         
  1551 Eastlake Avenue   1   10300 Campus Point Drive   1   Total properties excluded      
  1616 Eastlake Avenue   1   11119 North Torrey Pines Road   1  

from Same Properties

  38  
  285 Bear Hill Road   1   20 Walkup Drive   1   Same Properties   135  
                         
  343 Oyster Point Boulevard   1   3530/3550 John Hopkins Court   2   Total properties as of      
  400 Technology Square   1   620 Professional Drive   1  

March 31, 2013

  173  
                         
  4757 Nexus Center Drive   1   6275 Nancy Ridge Drive   1          
                         
  9800 Medical Center Drive   3       7          
                         
      9                  

(1)
Property count includes one development delivery, one property acquired since January 1, 2012, and five active development and redevelopment properties.

(2)
Represents two buildings included in our property listing as one property. One of the two buildings represents the ground-up development completed during the year ended December 31, 2012.

S-34


Table of Contents

        The following table presents a comparison of the components of NOI for our Same Properties and Non-Same Properties for the three months ended March 31, 2013, compared to the three months ended March 31, 2012, and a reconciliation of NOI to income from continuing operations, the most directly comparable financial measure (dollars in thousands):

 
  Three Months Ended March, 31,  
 
  2013   2012   $ Change   % Change  

Revenues:

                         

Rental—Same Properties

  $ 91,960   $ 91,109   $ 851     1 %

Rental—Non-Same Properties

    19,816     10,092     9,724     96  
                   

Total rental

    111,776     101,201     10,575     11  

Tenant recoveries—Same Properties

    30,297     28,828     1,469     5  

Tenant recoveries—Non-Same Properties

    5,314     3,054     2,260     74  
                   

Total tenant recoveries

    35,611     31,882     3,729     12  

Other income—Same Properties

    120     59     61     103  

Other income—Non-Same Properties

    2,873     2,569     304     12  
                   

Total other income

    2,993     2,628     365     14  

Total revenues—Same Properties

    122,377     119,996     2,381     2  

Total revenues—Non-Same Properties

    28,003     15,715     12,288     78  
                   

Total revenues

    150,380     135,711     14,669     11  

Expenses:

                         

Rental operations—Same Properties

    35,824     33,748     2,076     6  

Rental operations—Non-Same Properties

    9,400     6,705     2,695     40  
                   

Total rental operations

    45,224     40,453     4,771     12  

Net operating income:

                         

Net operating income—Same Properties

    86,553     86,248     305      

Net operating income—Non-Same Properties

    18,603     9,010     9,593     107  
                   

Total net operating income

    105,156     95,258     9,898     10  

Other expenses:

                         

General and administrative

    11,648     10,357     1,291     13  

Interest

    18,020     16,226     1,794     11  

Depreciation and amortization

    46,065     41,786     4,279     10  

Loss on early extinguishment of debt

        623     (623 )   (100 )
                   

Total other expenses

    75,733     68,992     6,741     10  

Income from continuing operations

  $ 29,423   $ 26,266   $ 3,157     12 %
                   

Net operating income—same properties—GAAP basis

 
$

86,553
 
$

86,248
 
$

305
   
 

Less: straight-line rent adjustments

    (516 )   (7,194 )   (6,678 )   (93 )
                   

Net operating income—same properties—cash basis

  $ 86,037   $ 79,054   $ 6,983     8.8 %
                   

S-35


Table of Contents


USE OF PROCEEDS

        We expect to receive approximately $494.3 million in net proceeds from the sale of the notes in this offering after payment of our expenses related to this offering and underwriting discounts and commissions. We intend to use the net proceeds from this offering to prepay $150 million of the outstanding principal balance of our 2016 unsecured senior bank term loan, to reduce the outstanding balance on our unsecured senior line of credit to zero, and to hold the remaining proceeds in cash and cash equivalents to fund near term opportunities related to development/redevelopment projects, to fund near term property acquisitions, and for general corporate purposes. As of March 31, 2013, we had approximately $0.9 billion available under our unsecured senior line of credit with a weighted average interest rate of approximately 1.40%. Our unsecured senior line of credit matures in April 2017, provided that we exercise our sole right to extend the maturity twice by an additional six months after each exercise. As of March 31, 2013, we had approximately $750 million outstanding under our 2016 unsecured senior bank term loan with a weighted average interest rate of approximately 2.39%. Our 2016 unsecured senior bank term loan matures in June 2016, provided that we exercise our sole right to extend the maturity by one year. Affiliates of each of J.P. Morgan Securities LLC, RBC Capital Markets, LLC, RBS Securities Inc., Barclays Capital Inc., Goldman Sachs & Co., Mitsubishi UFJ Securities (USA), Inc., PNC Capital Markets LLC, Scotia Capital (USA) Inc., BBVA Securities Inc., BNY Mellon Capital Markets, LLC, Credit Agricole Securities (USA) Inc., Credit Suisse Securities (USA) LLC, Fifth Third Securities, Inc., HSBC Securities (USA) Inc., The Huntington Investment Company, and TD Securities (USA) LLC are lenders under our unsecured senior line of credit. Affiliates of each of RBC Capital Markets, LLC, RBS Securities Inc., Mitsubishi UFJ Securities (USA), Inc., PNC Capital Markets LLC, Scotia Capital (USA) Inc., BBVA Securities Inc., and BNY Mellon Capital Markets, LLC are lenders under our 2016 unsecured senior bank term loan. See "Underwriting (Conflicts of Interest)."

S-36


Table of Contents


CAPITALIZATION

        The following table sets forth our capitalization as of March 31, 2013:

        The information set forth in the following table should be read in conjunction with, and is qualified in its entirety by, the financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, which are incorporated by reference into this prospectus supplement.

 
  As of March 31, 2013  
(Dollars in thousands, except per share amounts)
  Actual   Pro
Forma
  Pro
Forma As
Adjusted
 

Cash and cash equivalents

  $ 87,001   $ 87,001   $ 412,877  
               

Debt:

                   

Secured notes payable

  $ 730,714   $ 730,714   $ 730,714  

Unsecured senior notes payable

    549,816     549,816     1,048,376  

Unsecured senior line of credit

    554,000     18,392      

Unsecured senior bank term loans(1)

    1,350,000     1,350,000     1,200,000  

Alexandria Real Estate Equities, Inc.'s stockholders' equity:

                   

Preferred stock, $0.01 par value per share; 100,000,000 shares authorized:

                   

10,000,000 shares of 7.00% Series D Cumulative Convertible Preferred Stock authorized, issued and outstanding on an actual, as adjusted, and as further adjusted basis; $25.00 liquidation value

    250,000     250,000     250,000  

5,200,000 shares of 6.45% Series E Cumulative Redeemable Preferred Stock authorized, issued and outstanding on an actual, as adjusted, and as further adjusted basis; $25.00 liquidation value

    130,000     130,000     130,000  

Common stock, $0.01 par value per share; 100,000,000 shares authorized; 63,317,296, 70,907,296, and 70,907,296 shares issued and outstanding on an actual, as adjusted, and as further adjusted basis(2)

    633     709     709  

Excess stock, $0.01 par value per share; 200,000,000 shares authorized; 0 shares issued and outstanding on an actual, as adjusted, and as further adjusted basis

             

Additional paid-in capital

    3,075,860     3,611,392     3,611,392  

Accumulated other comprehensive loss(3)

    (22,890 )   (22,890 )   (22,890 )
               

Total capitalization

  $ 6,618,133   $ 6,618,133   $ 6,948,301  
               

(1)
Composed of our 2016 unsecured senior bank term loan and our 2017 unsecured senior bank term loan.
(2)
The information presented does not include 742,054 shares of our common stock that we have reserved for issuance under our Amended and Restated 1997 Stock Award and Incentive Plan.
(3)
Accumulated other comprehensive loss consists of $1,517 of unrealized gains on marketable securities, $16,486 of unrealized losses on interest rate swap agreements, and $7,921 of unrealized foreign currency translation losses.

S-37


Table of Contents


DESCRIPTION OF NOTES AND GUARANTEE

        The following description supplements, and to the extent inconsistent, amends and supersedes the description appearing in the accompanying prospectus under "Description of Debt Securities and Related Guarantees" and "Description of Global Securities." The following description summarizes certain terms and provisions of the notes and the indenture, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the actual terms and provisions of the notes and the indenture. The form of the indenture has been filed as an exhibit to the registration statement of which this prospectus supplement and the accompanying prospectus are deemed a part. Capitalized terms used but not otherwise defined herein shall have the meanings given to them in the notes or the indenture, as applicable. As used in this section, unless stated otherwise, the terms "we," "us," "our" or "the Company" refer to Alexandria Real Estate Equities, Inc. and not to any of its subsidiaries, and references to the "Operating Partnership" or "guarantor" refer solely to Alexandria Real Estate Equities, L.P. and not to any of its subsidiaries.


General

        The notes will be issued pursuant to an indenture, dated February 29, 2012, among us, the Operating Partnership, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (the base indenture), as supplemented by a supplemental indenture to be entered into among us, the Operating Partnership, as guarantor, and the trustee (the supplemental indenture, and together with the base indenture, the indenture). You may request copies of the indenture and the form of the notes from us as described in "Where You Can Find More Information" in the accompanying prospectus.

        The notes will be issued only in fully registered, book-entry form, in denominations of $2,000 and integral multiples of $1,000 in excess thereof, except under the limited circumstances described in the accompanying prospectus under "Description of Global Securities." The registered holder of a note will be treated as its owner for all purposes.

        If any interest payment date, stated maturity date or redemption date is not a business day, the payment otherwise required to be made on such date will be made on the next business day without any additional payment as a result of such delay. The term "business day" means, with respect to any note, any day, except a Saturday, Sunday or legal holiday in The City of New York on which banking institutions or the corporate trust office of the trustee are authorized or required by law, regulation or executive order to close. All payments will be made in U.S. dollars.

        The notes will be fully and unconditionally guaranteed by the Operating Partnership on a senior unsecured basis. See "—Guarantee" below.

        The terms of the notes provide that we are permitted to reduce interest payments and payments upon a redemption of notes otherwise payable to a holder for any amounts we are required to withhold by law. For example, non-United States holders of the notes may, under some circumstances, be subject to U.S. federal withholding tax with respect to payments of interest on the notes. See "Federal Income Tax Considerations" of this prospectus supplement and in the accompanying prospectus. We will set-off any such withholding tax that we are required to pay against payments of interest payable on the notes and payments upon a redemption of notes.


Ranking

        As of March 31, 2013, we had outstanding $730.7 million of secured indebtedness and $2.45 billion of senior unsecured indebtedness (exclusive of trade payables, distributions payable, accrued expenses and committed letters of credit) on a consolidated basis. All of our outstanding secured indebtedness as of March 31, 2013 was attributable to indebtedness of our subsidiaries other than the guarantor. As of

S-38


Table of Contents

March 31, 2013, all of our outstanding senior unsecured indebtedness was attributable only to indebtedness of the Company and the guarantor, and will rank pari passu with the notes.

        The notes will be our senior unsecured obligations and will rank equally with each other and with all of our other senior unsecured indebtedness. However, the notes will be effectively subordinated to our existing and future mortgages and other secured indebtedness (to the extent of the value of the collateral securing such indebtedness) and to all existing and future preferred equity and liabilities, whether secured or unsecured, of our subsidiaries other than the Operating Partnership.

        Except as described under "—Certain Covenants" and "—Limitations on Mergers and Other Transactions" in this prospectus supplement, the indenture governing the notes does not prohibit us or any of our subsidiaries from incurring additional indebtedness or issuing preferred equity in the future, nor does the indenture afford holders of the notes protection in the event of (1) a recapitalization transaction or other highly leveraged or similar transaction, (2) a change of control of us or (3) a merger, consolidation, reorganization, restructuring or transfer or lease of substantially all of our assets or similar transaction that may adversely affect the holders of the notes. We may, in the future, enter into certain transactions such as the sale of all or substantially all of our assets or a merger or consolidation that may increase the amount of our indebtedness or substantially change our assets, which may have an adverse effect on our ability to service our indebtedness, including the notes. See "Risk Factors—Risks Related to this Offering—The effective subordination of the notes and guarantee may limit our ability to satisfy our obligations under the notes." in this prospectus supplement.


Additional Notes

        The notes will initially be limited to an aggregate principal amount of $500,000,000. We may, without the consent of holders of the notes, increase the principal amount of the notes by issuing additional notes in the future on the same terms and conditions, except for any difference in the issue price and interest accrued prior to the issue date of the additional notes, and with the same CUSIP number as the notes offered hereby so long as such additional notes are fungible for U.S. federal income tax purposes with the notes offered hereby (as determined by us). The notes offered by this prospectus supplement and any additional notes would rank equally and ratably in right of payment and would be treated as a single series of debt securities for all purposes under the indenture.


Interest

        Interest on the notes will accrue at the rate of 3.90% per year from and including June 7, 2013 or the most recent interest payment date to which interest has been paid or provided for, and will be payable semi-annually in arrears on December 15 and June 15 of each year, beginning December 15, 2013. The interest so payable will be paid to each holder in whose name a note is registered at the close of business on the December 1 or June 1 (whether or not a business day) immediately preceding the applicable interest payment date. Interest on the notes will be computed on the basis of a 360-day year consisting of twelve 30-day months.

        If we redeem the notes in accordance with the terms of such note, we will pay accrued and unpaid interest and premium, if any, to the holder that surrenders such note for redemption. However, if a redemption falls after a record date and on or prior to the corresponding interest payment date, we will pay the full amount of accrued and unpaid interest and premium, if any, due on such interest payment date to the holder of record at the close of business on the corresponding record date.


Maturity

        The notes will mature on June 15, 2023 and will be paid against presentation and surrender thereof at the corporate trust office of the trustee unless earlier redeemed by us at our option as

S-39


Table of Contents

described under "—Our Redemption Rights" below. The notes will not be entitled to the benefits of, or be subject to, any sinking fund.


Our Redemption Rights

        At any time before 90 days prior to the maturity date, we may redeem the notes at our option and in our sole discretion, in whole or from time to time in part, at a redemption price equal to the sum of:

        If the notes are redeemed on or after 90 days prior to the maturity date, the redemption price will be equal to the sum of 100% of the principal amount of the notes being redeemed, plus accrued and unpaid interest thereon, if any, to, but excluding, the date of redemption, and will not include the Make-Whole Amount.

        As used herein:

        "Make-Whole Amount" means, in connection with any optional redemption of the notes, the excess, if any, as determined by the Company, of: (1) the aggregate present value as of the date of such redemption of each dollar of principal being redeemed or paid and the amount of interest (exclusive of interest accrued to the date of redemption) that would have been payable in respect of each such dollar if such redemption or accelerated payment had not been made, determined by discounting, on a semi-annual basis, such principal and interest at the Reinvestment Rate (determined by the Company on the third business day preceding the date a notice of redemption is given) from the respective dates on which such principal and interest would have been payable if such redemption or payment had not been made, over (2) the aggregate principal amount of the notes being redeemed or paid.

        "Reinvestment Rate" means 0.30% plus the arithmetic mean of the yields under the respective heading "Week Ending" published in the most recent Statistical Release under "Treasury Constant Maturities" for the maturity (rounded to the nearest month) corresponding to the remaining life to maturity, as of the date of the principal being redeemed or paid. If no maturity exactly corresponds to such maturity, yields for the two published maturities most closely corresponding to such maturity shall be calculated pursuant to the immediately preceding sentence and the Reinvestment Rate shall be interpolated or extrapolated from such yields on a straight-line basis, rounding in each of such relevant periods to the nearest month. For the purpose of calculating the Reinvestment Rate, the most recent Statistical Release published prior to the date of determination of the Make-Whole Amount shall be used.

        "Statistical Release" means that statistical release designated "H.15(519)" or any successor publication that is published weekly by the Federal Reserve System and that establishes annual yields on actively traded U.S. government securities adjusted to constant maturities, or, if such statistical release is not published at the time of any determination under the indenture, then such other reasonably comparable index the Company designates. If the format or content of the Statistical Release changes in a manner that precludes determination of the Treasury yield in the above manner, then the Treasury yield shall be determined in the manner that most closely approximates the above manner, as reasonably determined by us.

        Notice of any redemption will be mailed at least 30 days but not more than 60 days before the redemption date to each holder of the notes to be redeemed. Unless we default in payment of the redemption price, on and after the redemption date, interest will cease to accrue on the notes or portions thereof called for redemption.

S-40


Table of Contents

        If we decide to redeem the notes in part, the trustee will select the notes to be redeemed (in principal amounts of $2,000 and integral multiples of $1,000 in excess thereof) on a pro rata basis or such other method it deems fair and appropriate or is required by the depository for the notes.

        In the event of any redemption of notes in part, we will not be required to:

        If the paying agent holds funds sufficient to pay the redemption price of the notes on the redemption date, then on and after such date:

        Such will be the case whether or not book-entry transfer of the notes in book-entry form is made and whether or not notes in certificated form, together with the necessary endorsements, are delivered to the paying agent.

        We will not redeem the notes on any date if the principal amount of the notes has been accelerated, and such an acceleration has not been rescinded or cured on or prior to such date.


Certain Covenants

Limitations on Incurrence of Debt

        Limitation on Total Outstanding Debt.    The notes will provide that we will not, and will not permit any subsidiary to, incur any Debt, other than Intercompany Debt and guarantees of Debt incurred by us or our subsidiaries in compliance with the indenture governing the notes, if, immediately after giving effect to the incurrence of such Debt and the application of the proceeds thereof, the aggregate principal amount of all of our and our subsidiaries' outstanding Debt on a consolidated basis determined in accordance with generally accepted accounting principles is greater than 60% of the sum of (without duplication) (1) Total Assets as of the end of the calendar quarter covered in our Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, most recently filed with the Securities and Exchange Commission (or, if such filing is not permitted under the Exchange Act, with the trustee) prior to the incurrence of such additional Debt and (2) the purchase price of any real estate assets or mortgages receivable acquired, and the amount of any securities offering proceeds received (to the extent such proceeds were not used to acquire real estate assets or mortgages receivable or used to reduce Debt), by us or any subsidiary since the end of such calendar quarter, including those proceeds obtained in connection with the incurrence of such additional Debt.

        Secured Debt.    In addition to the foregoing limitation on the incurrence of Debt, the notes will provide that we will not, and will not permit any subsidiary to, incur any Debt, other than Intercompany Debt and guarantees of Debt incurred by us or our subsidiaries in compliance with the indenture governing the notes, secured by any mortgage, lien, charge, pledge, encumbrance or security interest of any kind upon any of our or any of our subsidiaries' property if, immediately after giving

S-41


Table of Contents

effect to the incurrence of such Debt and the application of the proceeds thereof, the aggregate principal amount of all of our and our subsidiaries' outstanding Debt on a consolidated basis which is secured by any mortgage, lien, charge, pledge, encumbrance or security interest on our or our subsidiaries' property is greater than 40% of the sum of (without duplication) (1) Total Assets as of the end of the calendar quarter covered in our Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, most recently filed with the Securities and Exchange Commission (or, if such filing is not permitted under the Exchange Act, with the trustee) prior to the incurrence of such additional Debt and (2) the purchase price of any real estate assets or mortgages receivable acquired, and the amount of any securities offering proceeds received (to the extent such proceeds were not used to acquire real estate assets or mortgages receivable or used to reduce Debt), by us or any of our subsidiaries since the end of such calendar quarter, including those proceeds obtained in connection with the incurrence of such additional Debt; provided, that for purposes of this limitation, the amount of obligations under capital leases shown as a liability on the Company's consolidated balance sheet shall be deducted from Debt and from Total Assets.

        Ratio of Consolidated EBITDA to Interest Expense.    The notes will provide that we will not, and will not permit any of our subsidiaries to, incur any Debt, other than Intercompany Debt and guarantees of Debt incurred by us or our subsidiaries in compliance with the indenture governing the notes, if the ratio of Consolidated EBITDA to Interest Expense for the four consecutive fiscal quarters most recently ended prior to the date on which such additional Debt is to be incurred shall have been less than 1.5 to 1.0, on an unaudited pro forma basis after giving effect to the incurrence of such additional Debt and to the application of the proceeds therefrom, and calculated on the assumption that: (1) such Debt and any other Debt incurred by us and our subsidiaries since the first day of such four-quarter period and the application of the proceeds therefrom, including to refinance other Debt, had occurred at the beginning of such period (except that, in making such computation, the amount of Debt under any revolving credit facility shall be computed based upon the average daily balance of such Debt during such period); (2) the repayment or retirement of any other Debt by us and our subsidiaries since the first day of such four-quarter period had been repaid or retired at the beginning of such period (except that, in making such computation, the amount of Debt under any revolving credit facility shall be computed based upon the average daily balance of such Debt during such period); (3) in the case of Acquired Debt or Debt incurred in connection with any acquisition since the first day of such four-quarter period, the related acquisition had occurred as of the first day of such period, with the appropriate adjustments with respect to such acquisition being included in such unaudited pro forma calculation; and (4) in the case of any acquisition or disposition by us or our subsidiaries of any asset or group of assets or other placement of any assets in service or removal of any assets from service by us or any of our subsidiaries since the first day of such four-quarter period, whether by merger, stock purchase or sale, or asset purchase or sale, such acquisition, disposition, placement in service or removal from service, or any related repayment of Debt had occurred as of the first day of such period, with the appropriate adjustments with respect to such acquisition, disposition, placement in service or removal from service, being included in such unaudited pro forma calculation and determined reasonably in good faith by us. If the Debt giving rise to the need to make the foregoing calculation or any other Debt incurred after the first day of the relevant four-quarter period bears interest at a floating rate then, for purposes of calculating the Interest Expense, the interest rate on such Debt shall be computed on a pro forma basis as if the average interest rate which would have been in effect during the entire such four-quarter period had been the applicable rate for the entire such period.

Maintenance of Unencumbered Total Asset Value

        The notes will provide that we, together with our subsidiaries, will at all times maintain an Unencumbered Total Asset Value in an amount not less than 150% of the aggregate outstanding principal amount of all our and our subsidiaries' unsecured Debt, taken as a whole.

S-42


Table of Contents

Insurance

        The notes will provide that we will, and will cause each of our subsidiaries to, maintain insurance with financially sound and reputable insurance companies against such risks and in such amounts as is customarily maintained by persons engaged in similar businesses or as may be required by applicable law.

Certain Definitions

        As used herein:

        "Acquired Debt" means Debt of a person (1) existing at the time such person becomes a subsidiary or (2) assumed in connection with the acquisition of assets from such person, in each case, other than Debt incurred in connection with, or in contemplation of, such person becoming a subsidiary or such acquisition. Acquired Debt shall be deemed to be incurred on the date of the related acquisition of assets from any person or the date the acquired person becomes a subsidiary.

        "Consolidated EBITDA" means, for any period of time, the net income (loss) of us and our subsidiaries, determined on a consolidated basis in accordance with generally accepted accounting principles for such period, before deductions for (without duplication):

For purposes of calculating Consolidated EBITDA, GAAP is not applicable with respect to the determination of all non-cash and non-recurring items which shall be determined reasonably and in good faith by us.

        "Debt" means any of our or any of our subsidiaries' indebtedness, whether or not contingent, in respect of (without duplication) (1) borrowed money evidenced by bonds, notes (including the notes offered hereby), debentures or similar instruments, (2) obligations secured by any mortgage, pledge, lien, charge, encumbrance or any security interest existing on property owned by us or any subsidiary, but only to the extent of the lesser of (a) the amount of obligations so secured and (b) the fair market value (determined in good faith by the board of directors of such person (as evidenced by an officers' certificate to the trustee) or, in the case of the Company or a subsidiary of the Company, by the Company's board of directors) of the property subject to such mortgage, pledge, lien, charge, encumbrance or security interest, (3) the reimbursement obligations, contingent or otherwise, in connection with any letters of credit actually issued or amounts representing the balance deferred and

S-43


Table of Contents

unpaid of the purchase price of any property or services, except any such balance that constitutes an accrued expense or trade payable, or all conditional sale obligations or obligations under any title retention agreement, or (4) any lease of property by us or any of our subsidiaries as lessee which is reflected on our consolidated balance sheet as a capitalized lease in accordance with generally accepted accounting principles; but only to the extent, in the case of items of indebtedness under (1) through (3) above, that any such items (other than letters of credit) would appear as a liability on our consolidated balance sheet in accordance with generally accepted accounting principles. The term "Debt" also includes, to the extent not otherwise included, any obligation of us or any of our subsidiaries to be liable for, or to pay, as obligor, guarantor or otherwise (other than for purposes of collection in the ordinary course of business or for the purposes of guaranteeing the payment of all amounts due and owing pursuant to leases to which we or any of our subsidiaries are a party and have assigned our or their interest, provided that such assignee of ours is not in default of any amounts due and owing under such leases), Debt of another person (other than us or any of our subsidiaries) (it being understood that Debt shall be deemed to be incurred by us or any of our subsidiaries whenever we or such subsidiary shall create, assume, guarantee or otherwise become liable in respect thereof).

        "Intercompany Debt" means Debt to which the only parties are any of us, the Operating Partnership and any subsidiary of us or the Operating Partnership; provided, however, that with respect to any such Debt of which we or the Operating Partnership is the borrower, such Debt is subordinate in right of payment to the notes.

        "Interest Expense" means, for any period of time, the aggregate amount of interest expense determined on a consolidated basis in accordance with generally accepted accounting principles for such period by us and our subsidiaries, but excluding (i) interest reserves funded from the proceeds of any loan, (ii) prepayment penalties, (iii) amortization of deferred financing costs, and (iv) swap ineffectiveness charges or charges attributable to transactions involving derivative instruments that do not qualify for hedge accounting in accordance with generally accepted accounting principles.

        "Total Assets" as of any date means the sum of (1) our and all of our subsidiaries' Undepreciated Real Estate Assets and (2) all of our and our subsidiaries' other assets determined in accordance with generally accepted accounting principles (but excluding accounts receivable and acquisition intangibles, including goodwill).

        "Undepreciated Real Estate Assets" as of any date means the cost (original cost plus capital improvements) of our and our subsidiaries' real estate assets on such date, before depreciation and amortization determined on a consolidated basis in accordance with generally accepted accounting principles.

        "Unencumbered Total Asset Value" as of any date means the sum of (1) those Undepreciated Real Estate Assets not encumbered by any mortgage, lien, charge, pledge or security interest and (2) all of our and our subsidiaries' other assets on a consolidated basis determined in accordance with generally accepted accounting principles (but excluding accounts receivable and acquisition intangibles, including goodwill), in each case which are unencumbered by any mortgage, lien, charge, pledge or security interest; provided, however, that, in determining Unencumbered Total Asset Value for purposes of the covenant set forth above in "—Maintenance of Unencumbered Total Asset Value," all investments by the Company and any subsidiary in unconsolidated joint ventures, unconsolidated limited partnerships, unconsolidated limited liability companies and other unconsolidated entities accounted for financial reporting purposes using the equity method of accounting in accordance with generally accepted accounting principles shall be excluded from Unencumbered Total Asset Value.


Guarantee

        The Operating Partnership will fully, unconditionally and absolutely guarantee our obligations under the notes, including the due and punctual payment of principal of and interest on the notes and

S-44


Table of Contents

all other amounts due and payable under the indenture, including any Make-Whole Amount, when and as such principal and interest and other amounts due and payable under the indenture (and, if applicable, any Make-Whole Amount) shall become due and payable, whether at stated maturity, by declaration of acceleration, call for redemption or otherwise. The guarantee will be a senior unsecured obligation of the Operating Partnership and will rank equally in right of payment with other senior unsecured obligations of the Operating Partnership.


Limitations on Mergers and Other Transactions

        We and the Operating Partnership may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to, any person, which we refer to as a successor person, unless:

        In the event of any transaction described in and complying with the conditions listed in the immediately preceding paragraphs in which we are not the surviving entity, the successor person formed or remaining shall succeed to, and be substituted for, and may exercise every right and power of ours under the indenture, and we shall be released from our obligations and covenants under the notes and the indenture.


Events of Default

        The indenture provides that the following events are "Events of Default" with respect to the notes:

S-45


Table of Contents

        As used herein:

        "Significant Subsidiary" means each Subsidiary that is a "significant subsidiary," if any, of the Company, as such term is defined in Regulation S-X under the Securities Act of 1933, as amended.

        "Subsidiary" means any corporation or other entity of which a majority of the voting power of the voting equity securities are owned directly or indirectly by the Company.

        No Event of Default with respect to the notes (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of default with respect to any other series of our debt securities. The occurrence of an Event of Default may constitute an event of default under our bank credit agreements in existence from time to time. In addition, the occurrence of certain events of default or an acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time.

        If an Event of Default with respect to the notes occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding notes may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of, and accrued and unpaid interest, if any, on all of the notes. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding notes. At any time after a declaration of acceleration with respect to notes has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding notes may rescind and annul the acceleration if all events of default, other than the non-payment of accelerated principal and interest, if any, with respect to the notes, have been cured or waived as provided in the indenture.

        The trustee will be required to give notice to the holders of notes within 90 days after a Default under the indenture unless the Default has been cured or waived. The trustee may withhold notice to the holders of the notes of any Default, except a Default in the payment of the principal of or interest on the notes, if specified responsible officers of the trustee in good faith determine that withholding the notice is in the interest of the holders. As used herein, the term "Default" means, with respect to the indenture and the notes, any event that is, or with the passage of time or giving of notice would be, an Event of Default. The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.

        The indenture provides that the trustee will be under no obligation to exercise any of its rights or powers under the indenture at the request of any holder of outstanding notes, unless the trustee receives indemnity satisfactory to it against any loss, liability or expense. Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding notes will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the notes.

S-46


Table of Contents

        No holder of the notes will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless:

        Notwithstanding the foregoing, the holder of the notes will have an absolute and unconditional right to receive payment of the principal of, premium, if any, and any interest on that debt security on or after the due dates expressed in the notes and to institute suit for the enforcement of payment.

        The indenture requires us, within 120 days after the end of the year, to furnish to the trustee a statement as to compliance with the indenture.


Modification and Waiver

        See "Description of Debt Securities and Related Guarantees—Modification and Waiver" in the accompanying prospectus.


Defeasance of Debt Securities and Certain Covenants in Certain Circumstances

        See "Description of Debt Securities and Related Guarantees—Defeasance and Covenants Defeasance" in the accompanying prospectus.


Trustee

        The Bank of New York Mellon Trust Company, N.A. will initially act as the trustee, registrar and paying agent for the notes, subject to replacement at our option.

        If an Event of Default has occurred and is continuing, the trustee will exercise the rights and powers vested in it by the indenture and use the same degree of care and skill in its exercise as a prudent man would exercise or use under the circumstances in the conduct of his own affairs. The trustee may refuse to perform any duty or exercise any right or power at the request or direction of any holder of the notes unless it receives indemnity satisfactory to it against any loss, liability or expense.

        If the trustee becomes one of our creditors, it will be subject to limitations on its rights to obtain payment of claims or to realize on some property received for any such claim, as security or otherwise. The trustee is permitted to engage in other transactions with us. If, however, it acquires any conflicting interest, it must eliminate that conflict or resign.


No Conversion or Exchange Rights

        The notes will not be convertible into or exchangeable for any capital stock of us or the Operating Partnership.


No Personal Liability of Directors, Officers, Employees and Stockholders

        No director, officer, employee or stockholder (past or present) of ours or the Operating Partnership, as such, will have any liability for any of our obligations or those of the Operating

S-47


Table of Contents

Partnership under the notes, the guarantee or the indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each holder of notes by accepting a note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the notes. The waiver may not be effective to waive liabilities under the federal securities laws.


Depository Procedures

        The following description of the operations and procedures of The Depository Trust Company, or DTC, is provided solely as a matter of convenience. These operations and procedures are solely within the control of the respective settlement systems and are subject to changes by them. None of us, the Operating Partnership, the trustee, or the underwriters take responsibility for these operations and procedures and urge investors to contact the system or their participants directly to discuss these matters.

        DTC has advised us that DTC is a limited-purpose trust company created to hold securities for its participating organizations (collectively, the Participants) and to facilitate the clearance and settlement of transactions in those securities between the Participants through electronic book-entry changes in accounts of its Participants. The Participants include securities brokers and dealers (including the underwriters), banks, trust companies, clearing corporations and other organizations. Access to DTC's system is also available to other entities such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a Participant, either directly or indirectly (collectively, the Indirect Participants). Persons who are not Participants may beneficially own securities held by or on behalf of DTC only through the Participants or the Indirect Participants. The ownership interests in, and transfers of ownership interests in, each security held by or on behalf of DTC are recorded on the records of the Participants and Indirect Participants.

        DTC has also advised us that, pursuant to procedures established by it:

        The laws of some states require that certain persons take physical delivery in definitive form of securities that they own. Consequently, the ability to transfer beneficial interests in a global note to such persons will be limited to that extent. Because DTC can act only on behalf of the Participants, which in turn act on behalf of the Indirect Participants, the ability of a person having beneficial interests in a global note to pledge such interests to persons that do not participate in the DTC system, or otherwise take actions in respect of such interests, may be affected by the lack of a physical certificate evidencing such interests.

        Except as described below, owners of interests in the global notes will not have notes registered in their names, will not receive physical delivery of notes in certificated form and will not be considered the registered owners or "holders" thereof under the indenture governing the notes for any purpose.

        Payments in respect of the principal of, and interest and premium, if any, on, a global note registered in the name of DTC or its nominee will be payable to DTC in its capacity as the registered holder under the indenture governing the notes. Under the terms of the indenture, we, the Company and the trustee will treat the persons in whose names the notes, including the global notes, are registered as the owners of the notes for the purpose of receiving payments and for all other purposes.

S-48


Table of Contents

Consequently, neither we, the Operating Partnership, the trustee nor any agent of us or the trustee has or will have any responsibility or liability for:

        DTC has advised us that its current practice, upon receipt of any payment in respect of securities such as the notes (including principal and interest), is to credit the accounts of the relevant Participants with the payment on the payment date unless DTC has reason to believe that it will not receive payment on such payment date. Each relevant Participant is credited with an amount proportionate to its beneficial ownership of an interest in the principal amount of the relevant security as shown on the records of DTC. Payments by the Participants and the Indirect Participants to the beneficial owners of notes will be governed by standing instructions and customary practices and will be the responsibility of the Participants or the Indirect Participants and will not be the responsibility of DTC, the trustee or us. Neither we nor the trustee will be liable for any delay by DTC or any of the Participants or the Indirect Participants in identifying the beneficial owners of the notes, and we and the trustee may conclusively rely on and will be protected in relying on instructions from DTC or its nominee for all purposes.

        Transfers between the Participants will be effected in accordance with DTC's procedures, and will be settled in same-day funds.

        DTC has advised us that it will take any action permitted to be taken by a holder of notes only at the direction of one or more Participants to whose account DTC has credited the interests in the global notes and only in respect of such portion of the aggregate principal amount at maturity of the notes as to which such Participant or Participants has or have given such direction. However, if there is an Event of Default under the notes, DTC reserves the right to exchange the global notes for legended notes in certificated form, and to distribute such notes to its Participants.


Transfer and Exchange

        See "Description of Global Securities" in the accompanying prospectus.


Same Day Settlement and Payment

        We will make payments in respect of the notes represented by the global notes (including principal, premium, if any, and interest) by wire transfer of immediately available funds to the accounts specified by DTC or its nominee. We will make all payments of principal, interest and premium, if any, with respect to certificated notes by wire transfer of immediately available funds to the accounts specified by the holders of the certificated notes or, if no such account is specified, by mailing a check to each such holder's registered address. The notes represented by the global notes are expected to trade in DTC's Same-Day Funds Settlement System, and any permitted secondary market trading activity in such notes will, therefore, be required by DTC to be settled in immediately available funds. We expect that secondary trading in any certificated notes will also be settled in immediately available funds.


Notices

        Except as otherwise provided in the indenture, notices to holders of the notes will be given by mail to the addresses of holders of the notes as they appear in the note register; provided that notices given

S-49


Table of Contents

to holders holding notes in book-entry form may be given through the facilities of DTC or any successor depository.


Governing Law

        The indenture, the notes and the guarantee will be governed by, and construed in accordance with, the law of the State of New York.

S-50


Table of Contents


FEDERAL INCOME TAX CONSIDERATIONS

        The following discussion summarizes the material U.S. federal income tax considerations relevant to the acquisition, ownership and disposition of the notes. What follows supplements the discussion in the accompanying prospectus and should be read in connection therewith. This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended (the "Code"), current and proposed Treasury regulations, administrative decisions and rulings of the Internal Revenue Service (the "IRS") and court decisions as of the date hereof, all of which are subject to change (possibly with retroactive effect) and all of which are subject to differing interpretation. The following summary does not address all aspects of U.S. federal income taxation that may be relevant to you in light of your particular circumstances or to persons subject to special treatment under the federal income tax laws. In particular, this discussion deals only with persons who hold the notes as capital assets within the meaning of the Code. Except as expressly provided below, this discussion does not address the tax treatment of special classes of persons, such as banks, insurance companies, tax-exempt organizations, financial institutions, broker-dealers, persons holding the notes as part of a hedge, straddle or other risk reduction, constructive sale or conversion transaction, U.S. expatriates, persons subject to the alternative minimum tax, foreign corporations, foreign estates or trusts and persons who are not citizens or residents of the United States. Furthermore, this discussion does not address any state, local, foreign or non-income tax considerations.

        For purposes of the following summary, a "U.S. Holder" generally refers to (i) an individual who is a citizen or resident of the United States; (ii) a corporation (including an entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States or of a political subdivision of the United States; (iii) an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or (iv) any trust if (1) a U.S. court is able to exercise primary supervision over the administration of such trust and one or more "United States persons" (within the meaning of the Code) have the authority to control all substantial decisions of the trust or (2) it has a valid election in place to be treated as a United States person. A "Non-U.S. Holder" generally refers to a person, other than an entity treated as a partnership for U.S. federal income tax purposes, that is not a U.S. Holder.

        If an entity treated as a partnership for U.S. federal income tax purposes is a beneficial owner of the notes, the U.S. federal income tax consequences to a partner in the partnership generally will depend on the status of the partner and the activities of the partnership. A holder that is a partnership, and the partners in such partnership, should consult their own tax advisors regarding the U.S. federal income tax considerations of an investment in the notes.

        THE DISCUSSION SET FORTH BELOW IS NOT INTENDED TO BE, NOR SHOULD IT BE CONSTRUED TO BE, LEGAL OR TAX ADVICE TO ANY PARTICULAR HOLDER. ACCORDINGLY, YOU SHOULD CONSULT YOUR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO YOUR PARTICULAR SITUATION AS WELL AS APPLICABLE STATE, LOCAL AND FOREIGN TAX LAWS.

Characterization of the Notes

        If we redeem the notes, we may be obligated to pay additional amounts in excess of stated principal and interest. See "Description of Notes and Guarantee—Our Redemption Rights." Notwithstanding the possible payment of such additional amounts, we intend to take the position that the notes should not be treated as "contingent payment debt instruments" for federal income tax purposes. If the IRS successfully challenged this position, and the notes were treated as contingent payment debt instruments, holders could be required to accrue interest income at a rate higher than the stated interest rate on the notes and to treat as ordinary income, rather than capital gain, any gain recognized on a sale, exchange or redemption of a note. Holders are urged to consult their tax advisors

S-51


Table of Contents

regarding the potential application to the notes of the contingent payment debt instrument rules and the consequences thereof. The remainder of this discussion assumes the notes will not be treated as contingent payment debt instruments.

Taxation of U.S. Holders

Payments of Interest

        Stated interest on a note generally will be taxable to a U.S. Holder as ordinary interest income at the time such interest is actually or constructively received, in accordance with such U.S. Holder's method of accounting for U.S. federal income tax purposes.

Sale, Exchange, or Retirement

        Upon the sale, exchange, retirement or other disposition of a note, a U.S. Holder will recognize gain or loss equal to the difference between the amount realized upon such sale, exchange, retirement or other disposition (less an amount equal to any accrued interest not previously included in income, which will be included in income as ordinary interest income) and the U.S. Holder's adjusted tax basis in the note. The amount realized by the U.S. Holder will include the amount of any cash and the fair market value of any other property received for the note. A U.S. Holder's adjusted tax basis in a note generally will be the cost of the note to such U.S. Holder, increased by any market discount (as discussed below) previously included in income with respect to the note, and decreased by the amount of any payment (other than a payment of qualified stated interest) received in respect of the note and any amortizable bond premium deducted by such holder.

        Subject to the discussion of market discount below, gain or loss realized on the sale, exchange, retirement or other disposition of a note generally will be capital gain or loss and will be long-term capital gain or loss if the note has been held for more than one year. The ability of U.S. Holders to deduct capital losses is subject to limitations under the Code.

Market Discount

        If a U.S. Holder purchases a note subsequent to its original issuance for an amount that is less than its stated redemption price at maturity, such difference will be treated as "market discount" unless such difference is less than a specified de minimis amount. Under the market discount rules, any principal payment on, or any gain on the sale, exchange, retirement or other disposition of, a note will be treated as ordinary income to the extent of accrued market discount not previously included in income. In addition, a holder may be required to defer, until the maturity of the note or its earlier disposition in a taxable transaction, the deduction of all or a portion of interest expense on any indebtedness attributable to such note.

        Market discount accrues ratably during the period from the date of acquisition to the maturity date of the note, unless a holder elects to accrue under a constant yield method. A holder may elect to include market discount in income currently as it accrues, in which case the rule described above regarding deferral of interest deductions will not apply. An election by a holder to include market discount in income currently, once made, applies to all market discount obligations acquired by such holder on or after the first taxable year to which the election applies and may not be revoked without the consent of the IRS.

Amortizable Bond Premium

        If a holder purchases a note for an amount in excess of the sum of all amounts payable on such note after the purchase date (other than qualified stated interest), such holder will be considered to have purchased such note with "amortizable bond premium" equal to such excess. A holder generally

S-52


Table of Contents

may elect to amortize such premium over the remaining term of the note under a constant yield method as an offset to interest when includible in income. A holder who elects to amortize bond premium must reduce its tax basis in the note by the amount of the premium amortized in any year. An election to amortize premium on a constant yield method will apply to all debt obligations held or subsequently acquired by the holder on or after the first day of the first taxable year to which the election applies. A holder may not revoke the election without the consent of the IRS.

Taxation of Non-U.S. Holders

Payments of Interest

        Under current U.S. federal income tax law and subject to the discussion below concerning backup withholding, principal and interest payments received from us or our agent generally will not be subject to U.S. federal income or withholding tax, except as provided below.

        Interest may be subject to a 30% withholding tax (or less under an applicable treaty, if any) if:

        A Non-U.S. Holder generally will satisfy the certification requirements if the Non-U.S. Holder certifies, under penalties of perjury, that it is not a "United States person" (within the meaning of the Code) and provides its name and address (which certification may generally be made on an IRS Form W-8BEN, or a successor form). Payments otherwise subject to withholding under the rules set forth above may nevertheless be exempt from withholding (or subject to withholding at a reduced rate) if the Non-U.S. Holder provides a properly executed IRS Form W-8BEN (or successor form) claiming an exemption from, or reduction in, withholding under the benefit of a tax treaty.

        A Non-U.S. Holder generally will be subject to tax in the same manner as a U.S. Holder with respect to payments of interest effectively connected with the conduct by the Non-U.S. Holder of a trade or business within the United States and, if required under an applicable tax treaty, a permanent establishment maintained in the United States. In some circumstances, such effectively connected income received by a corporate Non-U.S. Holder may be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be provided by an applicable treaty.

Sale, Exchange, or Retirement

        A Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax on any capital gain or market discount realized on the sale, exchange, retirement or other disposition of a note, provided that: (a) the gain is not effectively connected with the conduct of a trade or business within the United States and, if required under an applicable tax treaty, a permanent establishment maintained in the United States if certain tax treaties apply; and (b) in the case of a Non-U.S. Holder that is an individual, the Non-U.S. Holder is not present in the United States for 183 days or more in the taxable year of the sale, exchange or other disposition of the note. An individual Non-U.S. Holder

S-53


Table of Contents

present in the United States for 183 days or more in the taxable year of sale, exchange or other disposition, subject to certain additional conditions, will be subject to U.S. federal income tax at a rate of 30% on the gain realized on the sale, exchange or other disposition.

        A Non-U.S. Holder generally will be subject to tax in the same manner as a U.S. Holder with respect to gain realized on the sale, exchange, retirement or other disposition of a note if such gain is effectively connected with the conduct by the Non-U.S. Holder of a trade or business within the United States and, if required under an applicable tax treaty, a permanent establishment maintained in the United States. In some circumstances, such effectively connected gain received by a corporate Non-U.S. Holder may be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be provided by an applicable treaty.

Backup Withholding and Information Reporting

        In general, in the case of a U.S. Holder, other than certain exempt holders, we and other payors are required to report to the IRS all payments of principal and interest on the notes. In addition, we and other payors generally are required to report to the IRS any payment of proceeds of the sale of a note before maturity. Additionally, backup withholding generally will apply to any payments if a U.S. Holder fails to provide an accurate taxpayer identification number and certify that the taxpayer identification number is correct, the U.S. Holder is notified by the IRS that it has failed to report all interest and dividends required to be shown on its U.S. federal income tax returns, or the U.S. Holder does not certify that it has not underreported its interest and dividend income. If applicable, backup withholding will be imposed currently at a rate of 28%.

        In the case of a Non-U.S. Holder, backup withholding and information reporting generally will not apply to payments made if the Non-U.S. Holder provides the required certification that it is not a United States person, or the Non-U.S. Holder otherwise establishes an exemption, provided that the payor or withholding agent does not have actual knowledge that the holder is a United States person, or that the conditions of any exemption are not satisfied.

        In addition, payments of the proceeds from the sale of a note to or through a foreign office of a broker or the foreign office of a custodian, nominee, or other dealer acting on behalf of a holder generally will not be subject to information reporting or backup withholding. However, if the broker, custodian, nominee or other dealer is a United States person, the government of the United States or the government of any state or political subdivision of any state, or any agency or instrumentality of any of these governmental units, a controlled foreign corporation for U.S. federal income tax purposes, a foreign partnership that is either engaged in a trade or business within the United States or whose U.S. partners in the aggregate hold more than 50% of the income or capital interest in the partnership, a foreign person 50% or more of whose gross income for a certain period is effectively connected with a trade or business within the United States, or a U.S. branch of a foreign bank or insurance company, information reporting (but not backup withholding) generally will be required with respect to payments made to a Non-U.S. Holder unless the broker, custodian, nominee, or other dealer has documentation of such holder's foreign status and the broker, custodian, nominee, or other dealer has no actual knowledge to the contrary.

        Payment of the proceeds from a sale of a note to or through the U.S. office of a broker is subject to information reporting and backup withholding, unless the Non-U.S. Holder certifies as to its non-United States person status or otherwise establishes an exemption from information reporting and backup withholding.

        Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a holder's U.S. federal income tax liability provided the required information is furnished to the IRS.

S-54


Table of Contents


UNDERWRITING (CONFLICTS OF INTEREST)

        J.P. Morgan Securities LLC, RBC Capital Markets, LLC and RBS Securities Inc. are acting as representatives of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the principal amount of notes set forth opposite its name below.

Underwriter
  Principal
Amount of Notes
 

J.P. Morgan Securities LLC

  $ 103,750,000  

RBC Capital Markets, LLC

  $ 88,750,000  

RBS Securities Inc. 

  $ 88,750,000  

Barclays Capital Inc. 

  $ 26,250,000  

Goldman, Sachs & Co. 

  $ 26,250,000  

Mitsubishi UFJ Securities (USA), Inc. 

  $ 26,250,000  

PNC Capital Markets LLC

  $ 26,250,000  

Scotia Capital (USA) Inc. 

  $ 26,250,000  

BBVA Securities Inc. 

  $ 11,250,000  

BNY Mellon Capital Markets, LLC

  $ 11,250,000  

Credit Agricole Securities (USA) Inc. 

  $ 11,250,000  

Credit Suisse Securities (USA) LLC

  $ 11,250,000  

Fifth Third Securities, Inc. 

  $ 8,500,000  

HSBC Securities (USA) Inc. 

  $ 8,500,000  

The Huntington Investment Company

  $ 8,500,000  

JMP Securities LLC

  $ 8,500,000  

TD Securities (USA) LLC

  $ 8,500,000  

Total

  $ 500,000,000  
       

        Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to purchase all of the notes sold under the underwriting agreement if any of these notes are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated.

        We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities.

        The underwriters are offering the notes, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer's certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

Commissions and Discounts

        The representatives have advised us that the underwriters propose initially to offer the notes to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of 0.40% of the principal amount of the notes. The underwriters may allow, and those dealers may reallow, a concession not to exceed 0.25% of the principal amount of the notes on sales to other dealers. After the initial offering, the public offering price, concession or any other term of the offering may be changed.

S-55


Table of Contents

        The following table shows the public offering price, underwriting discounts and commissions and proceeds before expenses to us.

 
  Per Note   Total  

Public offering price

    99.712 % $ 498,560,000  

Underwriting discounts and commissions

    0.650 % $ 3,250,000  

Proceeds, before expenses, to us

    99.062 % $ 495,310,000  

        The expenses of the offering, not including the underwriting discounts and commissions, are estimated at $1,042,500 and are payable by us.

        The notes are a new issue of securities for which there currently is no market. We do not intend to apply for the notes to be listed on any securities exchange or to arrange for the notes to be quoted on any quotation system. The underwriters have advised us that they intend to make a market in the notes after completion of the offering and as permitted by applicable law. They are not obligated, however, to make a market in the notes and any market-making may be discontinued at any time at their sole discretion. However, we cannot assure you that the prices at which the notes will sell in the market after this offering will not be lower than the initial offering price or that an active trading market for the notes will develop and continue after this offering. Accordingly, no assurance can be given as to the development or liquidity of any market for the notes.

Price Stabilization, Short Positions

        In connection with the offering, the underwriters may purchase and sell our notes in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of notes than they are required to purchase in the offering. Stabilizing transactions consist of various bids for or purchases of the notes made by the underwriters in the open market prior to the completion of the offering.

        The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased notes sold by or for the account of such underwriter in stabilizing or short covering transactions.

        Similar to other purchase transactions, the underwriters' purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our notes or preventing or retarding a decline in the market price of our notes. As a result, the price of our notes may be higher than the price that might otherwise exist in the open market.

        Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our notes. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

Conflicts of Interest

        Affiliates of each of J.P. Morgan Securities LLC, RBC Capital Markets, LLC, RBS Securities Inc., Barclays Capital Inc., Goldman Sachs & Co., Mitsubishi UFJ Securities (USA), Inc., PNC Capital Markets LLC, Scotia Capital (USA) Inc., BBVA Securities Inc., BNY Mellon Capital Markets, LLC, Credit Agricole Securities (USA) Inc., Credit Suisse Securities (USA) LLC, Fifth Third Securities, Inc., HSBC Securities (USA) Inc., The Huntington Investment Company, and TD Securities (USA) LLC are lenders under our unsecured senior line of credit. A portion of the net proceeds from this offering will

S-56


Table of Contents

be used to reduce the outstanding balance of our unsecured senior line of credit to zero. See "Use of Proceeds." J.P. Morgan Securities LLC is a Joint Lead Arranger and Joint Bookrunner for our unsecured senior line of credit. An affiliate of J.P. Morgan Securities LLC is a Co-Syndication Agent for our unsecured senior line of credit. Affiliates of each of RBC Capital Markets, LLC, RBS Securities Inc., Barclays Capital Inc., Goldman, Sachs & Co., Scotia Capital (USA) Inc., BBVA Securities Inc. and Credit Agricole Securities (USA) Inc. are Co-Documentation Agents for our unsecured senior line of credit. As of March 31, 2013, we had approximately $0.9 billion available under our unsecured senior line of credit. Affiliates of each of RBC Capital Markets, LLC, RBS Securities Inc., Mitsubishi UFJ Securities (USA), Inc., PNC Capital Markets LLC, Scotia Capital (USA) Inc., BBVA Securities Inc., and BNY Mellon Capital Markets, LLC are lenders under our 2016 unsecured senior bank term loan. We intend to use the net proceeds from this offering to prepay $150 million of the outstanding principal balance of our 2016 unsecured senior bank term loan. See "Use of Proceeds." Affiliates of RBC Capital Markets, LLC and RBS Securities Inc. are Joint Lead Arrangers, Joint Book Running Managers, and Co-Syndication Agents for our 2016 unsecured senior bank term loan. Affiliates of each of Scotia Capital (USA) Inc. and BBVA Securities Inc. are Co-Documentation Agents for our 2016 unsecured senior bank term loan. As a result of the foregoing, the representatives have advised us that more than 5% of the net proceeds will be used to repay indebtedness under our unsecured senior line of credit and our 2016 unsecured senior bank term loan to banking affiliates of the underwriters.

Other Relationships

        Affiliates of each of J.P. Morgan Securities LLC, RBC Capital Markets, LLC, Barclays Capital, Inc., Goldman, Sachs & Co., Mitsubishi UFJ Securities (USA), Inc., PNC Capital Markets LLC, Scotia Capital (USA) Inc., and Credit Suisse Securities (USA) LLC are lenders under our 2017 unsecured senior bank term loan. J.P. Morgan Securities LLC is a Joint Lead Arranger and Joint Lead Book Runner for our 2017 unsecured senior bank term loan. An affiliate of J.P. Morgan Securities LLC is a Co-Syndication Agent for our 2017 unsecured senior bank term loan. Affiliates of each of RBC Capital Markets, LLC and Scotia Capital (USA) Inc. are Co-Documentation Agents for our 2017 unsecured senior bank term loan.

        The Bank of New York Mellon Trust Company, N.A., the trustee with respect to the notes, is an affiliate of BNY Mellon Capital Markets, LLC, one of the underwriters in this offering.

        The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking, financial advisory and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.

        In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. Certain of the underwriters or their affiliates that have a lending relationship with us routinely hedge their credit exposure to us consistent with their customary risk management policies. Typically, such underwriters and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities, including potentially the notes offered hereby. Any such short positions could adversely affect future trading prices of the notes offered hereby. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research

S-57


Table of Contents

views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

Extended Settlement

        We expect that delivery of the notes will be made to investors on or about June 7, 2013, which will be the seventh business day following the date of this prospectus supplement (such settlement being referred to as "T+7"). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in three business days unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on the date of pricing of the notes or the next two succeeding business days will be required, by virtue of the fact that the notes initially will settle in T+7, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisors.

Notice to Prospective Investors in the European Economic Area

        In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State"), each underwriter has represented and agreed that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the "Relevant Implementation Date") it has not made and will not make an offer of notes which are the subject of the offering contemplated by this prospectus supplement to the public in that Relevant Member State other than:

provided that no such offer of notes shall require the issuer or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.

        For the purposes of this provision, the expression an "offer of notes to the public in relation to any notes in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase or subscribe the notes, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.

        Each underwriter has represented and agreed that:

S-58


Table of Contents

Notice to Prospective Investors in Hong Kong

        The notes may not be offered or sold by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii) to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to the notes may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to notes which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder.

Notice to Prospective Investors in Japan

        The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (the "Financial Instruments and Exchange Law") and each underwriter has agreed that it will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan.

Notice to Prospective Investors in Singapore

        This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the notes may not be circulated or distributed, nor may the notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA"), (ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

        Where the notes are subscribed or purchased under Section 275 by a relevant person which is: (a) a corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest in that trust shall not be transferable for 6 months after that corporation or that trust has acquired the notes under Section 275 except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA; (2) where no consideration is given for the transfer; or (3) by operation of law.

S-59


Table of Contents


LEGAL MATTERS

        Certain legal matters relating to this offering will be passed upon for us by Morrison & Foerster LLP, Los Angeles, California, and certain matters with respect to Maryland law will be passed upon for us by Venable LLP, Baltimore, Maryland. Certain legal matters relating to this offering will be passed upon for the underwriters by Clifford Chance US LLP, New York, New York. Morrison & Foerster LLP and Clifford Chance US LLP will rely upon the opinion of Venable LLP as to all matters with respect to Maryland law.


EXPERTS

        The consolidated financial statements and schedule of Alexandria Real Estate Equities, Inc. and subsidiaries appearing in Alexandria Real Estate Equities, Inc.'s Annual Report (Form 10-K) for the year ended December 31, 2012, and effectiveness of Alexandria Real Estate Equities, Inc. and subsidiaries' internal control over financial reporting as of December 31, 2012, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their reports thereon included therein and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.

S-60


Table of Contents

PROSPECTUS

LOGO

Alexandria Real Estate Equities, Inc.

Common Stock   Rights
Preferred Stock   Warrants
Debt Securities

Alexandria Real Estate Equities, L.P.

Guarantees of Debt Securities

        We may issue Alexandria Real Estate Equities, Inc.'s shares of common stock, shares of preferred stock, rights, warrants or debt securities, and we or any selling security holders may offer and sell these securities from time to time in one or more offerings. Alexandria Real Estate Equities, L.P. may guarantee any debt securities that we issue under this prospectus.

        Each time that we or any selling security holders sell securities under this prospectus, we will provide a prospectus supplement or other offering material that will contain specific information about the terms of that offering. The prospectus supplement or other offering material may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and any prospectus supplement or other offering material, you should rely on the information in the prospectus supplement or such other offering material.

        We or any selling security holders may sell the securities to or through underwriters, and also to other purchasers or through agents. The names of the underwriters will be stated in the prospectus supplements or other offering material. We also may sell securities directly to investors. We will not receive any proceeds from the sale of common stock, preferred stock, rights, warrants or debt securities sold by any selling security holder. Alexandria Real Estate Equities, L.P. will not receive any proceeds from issuing guarantees of any debt securities.

        Our common stock is traded on the New York Stock Exchange under the symbol "ARE." Our 6.45% Series E cumulative redeemable preferred stock is traded on the New York Stock Exchange under the symbol "ARE PrE."

        Investing in our securities involves risks. See "Risk Factors" on page 1.

        Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

        The date of this prospectus is June 4, 2012.


Table of Contents


TABLE OF CONTENTS

About this Prospectus

    ii  

Risk Factors

    1  

Where You Can Find More Information

    1  

The Company

    3  

Securities That May Be Offered

    3  

Use of Proceeds

    4  

Consolidated Ratios of Earnings to Fixed Charges and Combined Fixed Charges and Preferred Stock Dividends

    5  

Description of Stock

    6  

Description of Rights

    12  

Description of Warrants

    13  

Description of Debt Securities and Related Guarantees

    14  

Description of Global Securities

    20  

Provisions of Maryland Law and of Our Charter and Bylaws

    23  

Federal Income Tax Considerations

    27  

Plan of Distribution

    40  

Legal Matters

    41  

Experts

    41  

Forward-Looking Statements

    41  

i


Table of Contents


ABOUT THIS PROSPECTUS

        Unless otherwise indicated or unless the context requires otherwise, all references in this prospectus to "we," "us," "our," "our company" or "the company" refer to Alexandria Real Estate Equities, Inc., a Maryland corporation, together with its consolidated subsidiaries, including Alexandria Real Estate Equities, Inc., L.P., a Delaware limited partnership.

        This prospectus is part of a "shelf" registration statement that we have filed with the United States Securities and Exchange Commission (the "SEC"). By using a shelf registration statement, we or any selling security holders may sell the common stock, preferred stock, rights, warrants or debt securities and the related guarantees described in this prospectus, any prospectus supplement or any other offering material:

        If any securities are sold pursuant to this prospectus by any persons other than us, we will, in a prospectus supplement, name the selling security holders, indicate the nature of any relationship such holders have had with us or any of our affiliates during the three years preceding such offering, state the amount of securities of the class owned by such security holder prior to the offering and the amount to be offered for the security holder's account, and state the amount and (if one percent or more) the percentage of the class to be owned by such security holder after completion of the offering.

        Neither this prospectus nor any accompanying prospectus supplement contains all of the information included in the registration statement, as permitted by the rules and regulations of the SEC. To understand fully the terms of the securities we or any selling security holders are offering with this prospectus, you should carefully read this entire prospectus, the applicable prospectus supplement and any other offering material, as well as the documents we have incorporated by reference. We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and therefore file reports and other information with the SEC. Statements contained in this prospectus and any accompanying prospectus supplement or other offering material about the provisions or contents of any agreement or other document are only summaries. If SEC rules or regulations require that any agreement or document be filed as an exhibit to the registration statement, you should refer to that agreement or document for its complete contents. You should not assume that the information in this prospectus, any prospectus supplement or any other offering material is accurate as of any date other than the date on the front of each document.

        YOU SHOULD CAREFULLY READ THIS PROSPECTUS, THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY APPLICABLE OTHER OFFERING MATERIAL, AS WELL AS THE DOCUMENTS WE HAVE INCORPORATED BY REFERENCE AS DESCRIBED UNDER THE SECTION ENTITLED "WHERE YOU CAN FIND MORE INFORMATION." WE ARE NOT MAKING AN OFFER OF THE SECURITIES OFFERED HEREBY IN ANY STATE WHERE SUCH OFFER OR SALE IS NOT PERMITTED.

        THIS PROSPECTUS MAY NOT BE USED TO SELL SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT OR OTHER OFFERING MATERIAL.

        You should rely only on the information contained in this prospectus, the applicable prospectus supplement and/or other offering materials, and the documents we have incorporated by reference. We have not authorized anyone to provide you with different information. You should not assume that the information provided by this prospectus, the applicable prospectus supplement, our other offering materials or the documents we have incorporated by reference is accurate as of any date other than the date of the respective document.

ii


Table of Contents


RISK FACTORS

        Investment in any securities offered pursuant to this prospectus involves risks. Before acquiring any offered securities pursuant to this prospectus, you should carefully consider the information contained or incorporated by reference in this prospectus or in any accompanying prospectus supplement, including, without limitation, the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and the other information contained or incorporated by reference in this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable accompanying prospectus supplement before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or a part of your investment in the offered securities. Please also refer to the section below entitled "Forward-Looking Statements."


WHERE YOU CAN FIND MORE INFORMATION

Where Documents are Filed; Copies of Documents

        We are subject to the informational requirements of the Exchange Act in accordance with which we file reports, proxy statements and other information with the SEC. This registration statement, the exhibits and schedules forming a part thereof, and the reports, proxy statements and other information we have filed with the SEC can be inspected and copied at the Public Reference Room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Such material also may be accessed by visiting the following internet website maintained by the SEC that contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC: http://www.sec.gov. In addition, our common stock and 6.45% Series E cumulative redeemable preferred stock are listed on the New York Stock Exchange, and similar information regarding us and the information we provide to the exchange may be inspected and copied at the offices of The New York Stock Exchange, 20 Broad Street, New York, New York 10005.

        You may also access further information about us by visiting our website at www.are.com. Please note that the information and materials found on our website, except for our SEC filings expressly described below, are not part of this prospectus and are not incorporated by reference into this prospectus.

Incorporation of Documents by Reference

        We have filed with the SEC a registration statement on Form S-3 with respect to the securities offered by this prospectus. This prospectus is a part of that registration statement. As allowed by the SEC, this prospectus does not contain all of the information you can find in the registration statement or the exhibits to the registration statement. Instead, the SEC allows us to "incorporate by reference" information into this prospectus. This means that we can disclose particular important information to you without actually including such information in this prospectus by simply referring you to another document that we filed separately with the SEC.

        The information we incorporate by reference is an important part of this prospectus and should be carefully read in conjunction with this prospectus and any prospectus supplement. Information that we file with the SEC after the date of this prospectus will automatically update and may supersede some of the information in this prospectus as well as information we previously filed with the SEC and that was incorporated by reference into this prospectus.

        The following documents are incorporated by reference into this prospectus:

1


Table of Contents

        If information in any of these incorporated documents conflicts with information in this prospectus, prospectus supplement or any other offering materials, you should rely on the most recent information. If information in an incorporated document conflicts with information in another incorporated document, you should rely on the information in the most recent incorporated document.

        You may request from us at no cost a copy of any document we incorporate by reference, excluding all exhibits to such incorporated documents (unless we have specifically incorporated by reference such exhibits either in this prospectus or in the incorporated document), by making such a request in writing or by telephone to the following address:

Alexandria Real Estate Equities, Inc.
385 East Colorado Boulevard, Suite 299
Pasadena, California 91101
Attention: Investor Relations
(626) 578-0777

        Except as provided above, no other information (including information on our website) is incorporated by reference into this prospectus.

2


Table of Contents


THE COMPANY

        Alexandria Real Estate Equities, Inc. is a Maryland corporation formed in October 1994 that has elected to be taxed as a real estate investment trust ("REIT") for federal income tax purposes. We are the largest owner, preeminent REIT and leading life science real estate company, focused principally on science-driven cluster development through the ownership, operation, management, selective acquisition, development, and redevelopment of properties containing life science laboratory space. We are the leading provider of high-quality, environmentally sustainable real estate, technical infrastructure, and services to the broad and diverse life science industry. Client tenants include leading multinational pharmaceutical companies, academic and medical institutions, public and private biotechnology entities, U.S. government research agencies, medical device companies, clean technology companies, venture capitalists, and life science product and service companies. Our primary business objective is to maximize stockholder value by providing our stockholders with the greatest possible total return based on a multifaceted platform of internal and external growth. Our operating platform is based on the principle of "clustering," with assets and operations located adjacent to life science entities driving growth and technological advances within each cluster.

        Alexandria Real Estate Equities, L.P. is a Delaware limited partnership of which our wholly owned subsidiary, ARE-QRS Corp., is the sole general partner. Alexandria Real Estate Equities, Inc. and ARE-QRS Corp. together hold all of the limited partnership interests in Alexandria Real Estate Equities, L.P. We directly or indirectly hold a majority of our interests in our properties and land, and conduct most of our operations, through Alexandria Real Estate Equities, L.P. and its subsidiaries.

        For additional information regarding our business, we refer you to our filings with the SEC incorporated by reference in this prospectus. See "Where You Can Find More Information."

        Our principal executive offices are located at 385 East Colorado Boulevard, Suite 299, Pasadena, California 91101 and our telephone number is (626) 578-0777.


SECURITIES THAT MAY BE OFFERED

        We or any selling security holder may offer and sell from time to time, at prices determined by negotiation, "at-the-market" or otherwise, as described by the applicable prospectus or other offering material, in one or more offerings, the following securities: